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Prion diseases, or transmissible spongiform encephalopathies (TSEs), are invariably fatal, 
typically species-specific neurodegenerative disorders affecting a number of mammalian species, 
including felids, caprids, cervids, mustelids, and humans. Propagated by a misfolded cellular 
protein that is ubiquitously expressed among all mammals, prion diseases are unique in that the 
infectious agent lacks nucleic acid and is able to persist in the environment for many years, 
maintaining infectivity through multiple routes of transmission. The role of the immune system 
during the acute and chronic phases of TSE infection is not well understood and is complicated by 
the fact that the infectious prion protein (PrPSc) shares the same primary structure as the normal 
cellular PrP protein (PrPC). Neuropathological lesions associated with prion disease have no 
apparent inflammatory infiltrate, although extensive gliosis and neuronal loss are hallmark 
observations. Additionally, the adaptive immune response does not appear to recognize PrPSc 
prions as foreign due to primary biochemical structure homology with PrPC. However, a number 
of recent findings have revealed a strong association between PrP and the immune system.  
 
While the physiological function of PrPC remains unclear, it has been shown to play a role in 
binding and transporting copper, and it also provides neuroprotection by inhibiting pro-apoptotic 
pathways. PrPC is most abundant in the central nervous system (CNS), with the second highest 
level of expression on the surface of various immune cells, including follicular dendritic cells 
(FDCs) and B cells. Expression of PrPC in the lymphoreticular system (LRS) has been linked to 
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PrPSc trafficking and replication in the periphery, perhaps by sequestering PrPSc-containing 
aggregates on the surface of immune cells and perpetuating the conversion of PrPC into the 
pathogenic form. Fibril depositions accumulate in the brain later in the course of disease and 
correspond to astrogliosis in affected neuronal tissue, implicating CNS immune involvement. 
Central nervous system immune responses likely play a role in prion neurodegenerative disease, 
potentially by contributing to neuronal cell death and spongiosis, or by initiating neuroprotective 
mechanisms.  
 
Identifying cytokines present throughout prion disease pathogenesis will help determine if 
immunopathology is initiated and may tease out other information about PrP-expressing immune 
cells and cytokine expression levels. In a pilot study, cytokine profiles were measured 
longitudinally in transgenic mice infected with prions as compared to control animals inoculated 
with normal brain homogenate (NBH). Serum cytokine levels were measured in cervidPrP-
expressing mice infected with chronic wasting disease (CWD) prions and control mice inoculated 
with NBH using the BioPlex suspension array system. We analyzed IL-1β, TNF-α, IFN-γ, GM-
CSF, IL-2, IL-6, IL-10, IL-4, and IL-5 at baseline levels, day one post-inoculation, and at two-
week intervals through terminal disease (data not shown). At the time of sacrifice, mouse serum 
and brain homogenate cytokine levels were also analyzed. As a distinct continuation of this study, 
TgA20 mice over-expressing murine PrPC 4- to 10-fold were infected with Rocky Mountain 
Laboratories (RML) mouse-adapted prions and serum cytokines analyzed in a similar longitudinal 
fashion. Additional sacrifices were made at 40, 60, and 80 days post-inoculation for cross-sectional 
comparison of cytokine profiles present in brain homogenate, where prion-induced lesions are 
most concentrated. We aimed to account for age- and sex-related cytokine variations, and, in 
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addition to the cytokines listed above, IL-12p70, IL-13, and IL-18 were also analyzed. This study 
represents the first longitudinal experiment analyzing systemic and neuro-inflammation in the 
same prion-infected animals throughout their entire disease course.  
 
Based on literature from other protein-misfolding diseases, we hypothesized a small increase in 
serum pro-inflammatory cytokines, specifically IL-1β, IL-6, IL-13, IL-18, TNF-α, and IFN-γ, 
present at 1 day post-inoculation (dpi), immediately following neuroinvasion around roughly 
60dpi, and prior to terminal disease. As with any inflammatory response, we anticipated a counter-
immune response through activation of immune regulatory pathways, represented by expression 
of the anti-inflammatory cytokine IL-10. Eventually, near terminal disease, severe 
neurodegeneration and chronic gliosis would exhaust central immune responses and presumptively 
cause any existing neuroprotective pathways to shut down. This loss of a chronic inflammatory 
state in the brain was projected to be represented by a decrease in—or absence of—pro- and anti-
inflammatory cytokines. 
 
Oxidative stress from a chronic pro-inflammatory state has been identified in a number of 
neurodegenerative diseases as a mechanism leading to neuronal vacuolation and apoptosis, but 
remains to be distinctly identified in prion disease models and is complicated by propagation of 
PrPSc in the LRS prior to neuroinvasion. The aims of the current study are to unveil significant 
pro- and anti-inflammatory responses as represented by cytokine profiles in the brain and periphery 
throughout the course of disease following intraperitoneal (IP) inoculation in a murine scrapie 
animal model.   
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Our findings show IL-2 and IL-5 had the most significant and consistent expression throughout 
the disease course. As both treatment groups were affected similarly, cytokine data is suggested to 
reflect over-expression of PrPC in TgA20 mice or relate to transgene insertion of Prnp gene copies 
within the transgenic model. Intermittent cytokine spikes among individual and grouped animals 
from both treatment groups were observed occasionally throughout the range of time points that 
were sampled and correlate to non-specific transient inflammatory responses unrelated to prion 
infection. Cross-sectional analysis of cytokines in brain homogenate showed a profile distinct of 
that observed in the periphery, with a single male RML-infected mouse showing a pro-
inflammatory response comparable to LPS-induced controls.  
 
The observed cytokine profiles provide insight into the alterations of immune cellular pathways 
resulting from PrPC overexpression and reinforce the physiologic role of PrP in T lymphocyte 
activation and subsequent B lymphocyte activation by T helper subsets. The role of mononuclear 
cell involvement was investigated through quantitation of MCP-1 via ELISA, and revealed 
expression levels well below LPS-induced controls in mouse serum but significantly increased 
expression levels in pooled brain homogenate of RML-male TgA20s. Unexpected cytokine profile 
expression, taken together with the survival curve and neuropathology from this study, reveal 
unique relationships and patterns of PrPC in the immune system and prion disease progression to 
terminal disease.  
 
Our findings support those of others, such as the involvement of cofilin-actin rods disrupting 
neuronal transport and contributing to synaptic loss prior to neuronal vacuolation and cell death. 
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Amyloid fibrils participate in interactions with PrPC to induce neuroinflammation via NOX 
activity. Similarly, Aβ and pro-inflammatory cytokines signal through similar, PrPC-dependent 
pathways to form axonal rods and contribute to synaptic loss. Additionally, metal cations (Cu, Mn, 
Mg, Fe) with unknown implications in prion pathogenesis were investigated in cervidized mice to 
determine their role in cervid disease progression. These results show that increased [Cu] resulted 
in decreased survival times and confirmed alterations in pro-inflammatory gene mRNA transcripts 
as well as protein expression in these same mice, further reinforcing the involvement of the 
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Prion diseases are described as invariably fatal neurodegenerative disorders caused by 
disseminated deposition of misfolded protein plaques throughout the central nervous system 
(CNS), resulting in vacuolation and eventually neuronal loss. Once believed to be a chronic 
infection induced by a slow virus, overwhelming evidence indicates infectious agent, PrPSc, is a 
misfolded version of the cellular prion protein (PrPC), lacking informative genetic material while 
retaining transmissibility (Prusiner, 1982). This “protein-only” hypothesis paved the way for 
research on transmissible spongiform encephalopathies (TSE) and led to the coined term “prion.” 
 
Scrapie was first described in 1732 and is the oldest known prion disease affecting captive sheep 
and goats. While scrapie is classified as a naturally occurring prion disease, Kuru and Bovine 
Spongiform Encephalopthy (BSE, aka mad cow disease) occur “unnaturally” as a result of 
ritualistic cannibalism and consumption of prion-contaminated bone meal product, respectively. 
Other factors tie into the infectivity of prions, with evidence of sporadic disease (Hsiao et al., 
1989), genetic susceptibilities (Hsiao et al., 1989; Collinge, 1997), and important biochemical 
properties of the prion protein itself (Rogers et al., 1993; Silveira et al., 2005). 
 
The exact structure of PrPSc and how it causes neurotoxicity is not known, however, once 
misfolded it has the ability to convert cellular, alpha-helical PrPC into the infectious, beta-pleated 
form which contains a resilient protease-resistant core (McKinley, Bolton, & Prusiner, 1983). 
PrPSc oligomers and fibrils persist in the environment for extremely long periods of time due to 
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their resistance to high temperatures, ultraviolet irradiation, proteinase K degradation, as well as 
other decontamination methods and denaturing conditions commonly used against bacteria and 
viruses (Prusiner, 1982, Weissmann et al., 1996). This begs the questions of how a protein that is 
ubiquitously expressed among all mammalian species: 1. Misfolds to become infectious? 2. Causes 
irreversible, chronic neurodegenerative disease? 3. Gains resistance to common decontamination 
practices? 4. Achieves strain properties among certain like-species, while other species appear to 
be resistant to infection? 5. Accomplishes all of this without eliciting a response from the body’s 
primary defenses—the immune system?       
 
Humans suffer from a number of distinct prion diseases including Creutzfeldt-Jakob Disease 
(CJD), Gerstmann-Straussler-Scheinker (GSS) syndrome, and fatal familial insomnia (FFI) - all 
of which can be inherited through extremely rare, autosomal dominant mutations of the Prnp gene 
encoding PrPC (Doh-ura et al., 1989; Goldfarb et al., 1991; Hsiao et al., 1989; Hsiao et al., 1990a/b; 
Owen, 1989), or can arise sporadically (Palmer et al., 1991). In addition, variant CJD (vCJD) is a 
new CJD-like syndrome that appears to be linked to consumption of prion-contaminated meat 
distributed from the UK following the emergence of bovine spongiform encephalopathy in the 
early 1990s (Aguzzi & Weissmann, 1996b; Bruce et al., 1997; Chazot et al., 1996; Collinge et al., 
1996; Hill et al., 1997a). Clinical presentation of certain human prion diseases can be strikingly 
similar to other human neurodegenerative disorders, but differences in the time to terminal disease 
and lesion profiles within the CNS typically sets them apart (Aguzzi & Weissmann, 1996b; 
Lasmezas et al., 1996). Despite this, and without a reliable ante-mortem diagnostic assay, it is 
estimated that a large number of prion-infected people are misdiagnosed as having frontotemporal 
dementia or Alzheimer’s Disease (AD), creating a legitimate public health concern (Doran & 
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Larner, 2004; Roberson et al., 2005; Tsivgoulis et al., 2014). Confirmed cases of prion diseases 
being acquired iatrogenically or from sub-clinically infected blood and tissue (dura graft) donors 
(Houston et al., 2000; Kobayashi et al., 2015; Llewelyn et al., 2004) add to this concern.  
 
Chronic wasting disease (CWD) is a prion disease affecting wild and captive populations of deer, 
elk, and moose in North America, Canada, and, as of 2001, South Korea. Classified as the only 
naturally-occurring prion disease of free-ranging animals, CWD was first described just 48 years 
ago, and the origin remains unclear. Multiple hypotheses exist to explain the sudden appearance 
of CWD - the most plausible involves horizontal or environmental transmission from scrapie-
infected sheep housed at an outdoor facility in Fort Collins, CO, in 1967, where it was first reported 
by Colorado Parks and Wildlife. However, scrapie was first described in 1732, and without nucleic 
acid or any previous evidence of prions crossing a species barrier, the emergence of CWD still 
eludes us. Little evidence exists supporting the hypothesis that consumption of CWD-infected 
meat puts humans at risk of developing prion disease. Although, the spike of vCJD cases in the 
UK, presumptively from the BSE outbreak, suggests that we exercise caution.  
 
Bovine Spongiform Encephalopathy (BSE) tells a different story than CWD.  Prions from BSE-
infected animals have crossed multiple species barriers, including humans, felines, and ungulates. 
It is unknown how BSE prions gained the ability to cross multiple species barriers, and, while all 
potential vCJD cases cannot definitively be traced back to the BSE outbreak in the UK, evidence 
strongly suggests a correlation (Aguzzi and Weissmann, 1996b, Bruce et al., 1997; Collinge et al., 
1996; Ziedler et al., 1997). In order to understand the phenomena being observed with BSE, we 
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must gain a stronger understanding for the physiological role of PrPC and how it behaves once 
converted to PrPSc.  
 
The cellular prion protein is a 36 kDa glycoprotein that is rich in alpha helices and linked to the 
cellular membrane through a glycophosphatidylinositol (GPI) anchor (Stahl et al., 1992). The 
primary protein consists of roughly 200 amino acids - give or take for different species – with a 
structured C-terminal domain and a non-structured N-terminal domain (AA 23-120). One of three 
glycosylation sites is present on the N-terminus, as well as an octapeptide repeat region and two 
histidines which bind copper with high affinity (Brown et al., 1997a). The protein’s GPI anchor 
and remaining glycosylation sites compose the C-terminal domain, in addition to a single disulfide 
bond connecting helices two and three. Cellular PrP is typically concentrated to lipid rafts of the 
plasma membrane and has a number of proposed, redundant functions, due to the fact that PrP 
knockout (PrP0/0) mice do not exhibit any overt dysfunctions and live relatively normal lives 
(Bueler, 1992; Bueler, 1993 Hsiao et al., 1989). 
 
Interestingly, PrPC itself appears to be an essential factor for fatal prion infection, ultimately 
elicited by PrPSc (Bueler et al., 1993). PrP0/0 mice inoculated with prions are completely resistant 
to prion-induced neurodegeneration but may display altered behavior or physiology (Bueler et al., 
1993; Prusiner et al., 1993; Tobler et al., 1996). Mouse models where PrPC is anchorless (i.e. 
lacking the GPI-portion of PrP) rather than attached to the cell membrane show a decreased 
infectivity of PrPSc, as well as distinct, minimal clinical disease, more similar to that of AD than 
scrapie (Chesebro et al., 2005). This suggests that PrPC being “used up” by autoconversion to PrPSc 
is not sufficient enough to cause disease (i.e. loss of function of PrPC alone cannot account for 
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prion neurodegeneration). If animal models can live relatively normal lives without expression of 
PrP in its normal form, then it suffices to say that formation of PrPSc must induce pathologic 
alterations to result in terminal disease. Since both forms of the prion protein are required (Bueler 
et al., 1993), however, it implies that PrPC-PrPSc interaction initiates an intracellular signal through 
GPI-linked PrPC, inducing neurotoxicity (Chesebro et al., 2005; Mallucci et al., 2003).  
 
Interestingly, new paradigms of prion formation have been found in mammalian innate immune 
systems. Analogs of PrPC that display conformational changes and reversible fibril formation have 
been found to be crucial cytoprotective immune mechanisms (Hou et al., 2011). Viral infection of 
murine cells activates RIG-I-like pathways, which, in turn activate mitochondrial antiviral 
signaling proteins (MAVS) to fibrilize like prions and causes activation of the transcription factors 
IRF-3 and NFκB. Type I interferons are then produced in order to establish an antiviral state. One 
can see how reversible fibril formation—with similar structure to prion fibrils—as an essential 
factor for important antiviral immune pathways, is an incredibly valuable finding. It has since been 
proposed that PrPC may be cytoprotective under stress (Flechsig and Weissmann, 2004; Roucou 
and LeBlanc, 2005; Westergard et al., 2007) as seen in other prion models, and a physiological 
change in the fibril somehow makes fibril formation irreversible, and, over time, failure to clear 
these structures becomes pathogenic.  
 
PrPC is translated from Prnp gene transcripts, some polymorphisms of which are linked to a variety 
of inherited human prion disorders, as mentioned above. The prion protein proceeds through the 
endoplasmic reticulum and Golgi apparatus for post-translational modifications and glycosylation 
before being transported to the cell surface. Once there, it is thought that PrPC plays a role in cell 
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adhesion, cell signaling, and/or binding copper in a pH dependent manner to cause PrPC 
internalization into the cell (Kiachopoulos et al., 2004; Pauly & Harris, 1998; Perera & Hooper, 
2001). While it is known in other neurodegenerative diseases such as AD, PD, and ALS that the 
cellular toxicity is mediated by oxidative stress in apoptotic pathways, the cellular mechanisms 
underlying neurotoxic prion diseases are less clearly defined (Giese et al., 1995; Williams et al., 
1997). 
 
If PrPC  PrPSc conversion is causing oxidative stress or activating certain cellular pathways to 
cause neurotoxicity, analyzing cell signaling molecules such as pro- and anti-inflammatory 
cytokines may reveal clues about the pathological processes taking place and the cellular players 
involved. Indeed, neuropathological lesions associated with prion disease do not recruit immune 
cells, as shown by a complete lack of inflammatory infiltrate near PrPSc deposits or spongiform 
lesions (Aucouturier et al., 2000; Berg, 1994). Additionally, prions do not appear to induce an 
adaptive antibody response, possibly due to the identical primary amino acid sequence of PrPC and 
PrPSc (Porter, Porter, & Cox, 1973). Instead, once in the brain, prions hide undetected, silently 
disturbing neuronal homeostasis until PrPSc deposition and neuronal vacuolation become apparent 
histologically along with extensive astrogliosis and microgliosis. Eventually, synaptic loss and 
spongiosis is so great that clinical symptoms arise and disease progresses uninhibited to complete 
paralysis and/or multi-organ shutdown.  
 
But what is happening during these long incubation periods, prior to neuroinvasion? How do prions 
enter the body, make their way to the brain, and what takes them so long to do so? Multiple routes 
of transmission have been proposed for acquired prion diseases, including horizontal transmission 
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via contact/ingestion of contaminated bodily fluids, environmental transmission via ingestion or 
inhalation of prion-contaminated fomites (soil, water, etc.), and transfusion or transplantation of 
blood and/or various medical devices. The potential of vertical transmission is currently being 
investigated. Once ingested, prions are found in tonsils (Hill et al., 1997), survive the acidic 
environment of the stomach, and proceed to the small intestine, where they are sampled by M cells 
and taken up into mucosal associated lymphoid tissues, such as the Peyer’s patches (Donaldson et 
al., 2012). This process is expedited in the presence of inflammation/epithelial damage (Sigurdson 
et al., 2009).  Conversely, prions have also been shown to efficiently transmit disease via intranasal 
inoculation with shorter incubation times, possibly by entering the olfactory epithelium and 
bypassing peripheral replication (DeJoia et al., 2006; Kincaid & Bartz, 2007).  
 
Surprisingly, the hallmark neuropathological profile seen in prion disease is not observed in the 
periphery. Prion diseases are characterized by species tropism, pathological profiles in the brain, 
clinical presentation, and time course of disease, but that doesn’t mean that infectious PrPSc 
deposits are exclusively neurotropic. Following central or peripheral inoculation, in the end-stages 
of disease PrPSc depositions are found in many areas throughout the body with no apparent 
pathological changes in the parenchyma of peripheral organs. Numerous secondary lymphoid 
organs, muscle tissue, and other areas of chronic inflammation are shown to have high titers of 
PrPSc at terminal disease (Heikenwalder et al., 2005), but with no interruption of the physiological 
function of that organ (Fraser et al., 1996). Only when PrPSc contacts a GPI-anchored, PrPC-
expressing cell within the central nervous system is the result pathologic (Baldwin et al., 1992; 
Brown, Schmidt, & Kretzschmar, 1995; Gellman & Gibson, 1996). If we understand which cells 
are harboring, transporting, and aiding replication of prions in the periphery during the 
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months/years of incubation period, we could potentially intervene prior to neuroinvasion and stop 
the progression of disease.  
 
Involvement of the LRS during prion disease is intriguing because of an apparent failure to induce 
an inflammatory or adaptive immune response yet clear association with PrP, suggesting a role in 
sequestration, replication, and/or transport of the prion protein. Prion replication in peripheral 
lymphoid tissues prior to neuroinvasion is a key component in a number of prion diseases, 
including scrapie (Fraser et al., 1996), CWD, vCJD, and BSE. By looking closely at the cellular 
signals present throughout prion infection, we hope to tease out more information about which 
cells are involved and how/or when certain events related to prion propagation and neuroinvasion 
are taking place. The normal linear progression of activation of the immune system in response to 
pathogen-associated molecular patterns involves positive feedback mechanisms and cell-specific 
signaling pathways for initial stimulation and continued activation. It is no wonder then, that 
immune components and cellular players involved in prion disease pathogenesis also display a 
certain degree of cellular interdependence, with monocytes and dendritic cells bridging the gap 
between innate and adaptive immunity.  
 
A number of these immune cell types have already been identified, and not surprisingly they 
involve a variety of immune cells which express PrPC at levels second highest to the CNS 
(Cashman et al., 1990; DeArmond et al., 1986). Amongst these are B lymphocytes, T lymphocytes, 
natural killer (NK) cells, platelets, erythrocytes, monocytes, dendritic cells (DCs), and, most 
importantly, follicular dendritic cells (FDCs) (Cashman et al., 1990; Clarke & Kimberlin, 1984; 
Dodelet & Cashman, 1998; Fraser & Farquhar, 1987). Dürig et al. (2000) further characterized 
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PrPC expression patterns on peripheral cells in circulation and discovered similar expression levels 
among T lymphocytes, NK cells, and monocytes, while B cells displayed significantly lower levels 
of PrPC, contrasting the findings of Cashman et al. (1990).  
 
The complement cascade has also been verified in prion and AD pathogenesis, shown by direct 
binding of C3, C1q, and Factor H to abnormal prion protein (Blanquet-Grossard et al., 2005; 
Mitchell et al., 2007; Sim et al., 2007) and amyloid (Jiang et al., 1994). Accelerated peripheral 
prion pathogenesis is correlated with complement factors C3, C1q, and CD21/CD35 receptors on 
the surface of FDCs (Aucouturier, 2001; Beringue et al., 2000; Zabel et al., 2007), and inhibition 
of neuroinvasion was observed following low-dose prion inoculation into C1q- and/or Bf/C2-KO 
mice (Klein et al., 2001). Previous researchers within our lab also demonstrated that CD21/CD35-
/- mice do not develop terminal disease (Michel et a., 2012) and C3 expression in murine CWD 
models accelerates disease (Michel et al., 2013).   
 
It is well known that FDCs play a key role in peripheral prion propagation (Brown et al., 1999; 
Fraser & Farquhar 1987; Montrasio et al., 2000), however, DCs, monocytes, and macrophages 
show conflicting results (Aucouturier et al., 2001; Beringue et al., 2000; Beringue et al., 2002; 
Wathne & Mabbott, 2012). Indeed, PrPC expression on myeloid cells is important for their 
maturation, and PrP-/- models display compromised stimulation of T cells by DCs (Ballerini et al., 
2006; Dürig et al., 2000).     
 
Evaluation of prion disease progression during the time between inoculation and terminal stages 
of disease has largely been neglected. This is partly due to the exceptionally long incubation 
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periods observed in chronic neurodegenerative diseases and is exacerbated by the fact that prion 
protein species barriers have limited the development of animal models. Various experimental 
methods have now been established to overcome these issues, such as transgenic rodent models 
over-expressing the prion protein, mouse-adapted scrapie prion strains, cervidized mice, and 
alternative routes of inoculation (i.e. intracerebral, or IC) which expedite disease progression. 
Different prion disease strains, animal models, and routes of inoculation all result in variable 
clinical and pathological prion disease manifestations. While one experimental model might not 
necessarily be better than another, certain disease models are preferable in studies of prion 
pathogenesis and immune involvement.  
 
A few investigators have looked at cytokine and chemokine gene transcript levels during prion 
infection through RT-PCR, and found these results to be non-representative of the actual functional 
protein levels being translated. The majority of experimental models investigating prion 
immunopathogenesis choose to employ IC inoculation, as opposed to peripheral routes. While this 
may reduce incubation period, IC inoculation bypasses peripheral lymphotropic prion replication 
and induces a level of traumatic injury to the brain which is undesirable when analyzing immune 
cellular pathways.  An ideal—but unrealistic—model would closely resemble the natural host and 
natural route of inoculation, express a normal level of prion protein and have an intact immune 
cell phenotype, but have a reasonable incubation period and retain pathologic lesions characteristic 
of that particular prion disease/strain. For this study, a mouse-adapted scrapie inoculum (RML) 
was injected intraperitoneally (IP) in TgA20 mice overexpressing the murine prion protein 4- to 
10-fold (Chandler, 1961; Fischer et al., 1996). This transgenic model and inoculum combo have 
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been used in prion research by other groups also investigating prion immunopathogenesis, making 
for more relevant data comparison.  
 
In order to analyze functional protein levels of immune cell signaling molecules, we chose to 
employ the BioPlex suspension array system to quantitate serum cytokine levels. This relatively 
new multiplex immunoassay combines the sample preparation of an ELISA with the technology 
of flow cytometry for sensitive measurement of multiple analytes from a single, minute sample 
size (~25µl). Magnetic beads conjugated to antibody specific for different analytes (via kits from 
eBioscience) are distinctly colored using ratios of internal red and infrared dyes, allowing the 
BioPlex machine to differentiate between analytes (Figure 1). An antibody mixture is incubated 
with a small sample of serum and cytokine levels are determined using a secondary biotinylated 
detection antibody (Figure 2). A streptavidin-PE reporter dye is excited by lasers and quantitated 
based on the standard curve generated. This assay allows for the measurement of multiple 
cytokines from a small sample size, and, for our study, was easily optimized for analysis of mouse 
brain homogenate supernatant as well. The variety of eBioscience magnetic bead kits also provided 
a somewhat customized cytokine array, with a comprehensive Th1/Th2 cytokine 11-plex kit 




Figure 1 (a-c): BioPlex Suspension Array System-Beads 
Magnetic beads are impregnated with different ratios of red and infrared dyes, making them 
distinctly recognizable by the red classification laser (a & b). Bead region ratios are assigned to a 
particular analyte depending on the detection antibody conjugated to that bead and entered into the 
BioPlex machine. Sample is incubated with a customized bead mixture, similar to an ELISA (c).   
 
Figure 2: BioPlex Suspension Array Overview 
Samples are prepared similar to an ELISA, except detection antibodies are conjugated to magnetic 
beads rather than the plate bottom to allow for multiple analyte detection from a single sample. 
Flow Cytometry is then used to quantitate protein expression through detection of biotinylated 
antibody with streptavidin-PE.  
 
 
Specifically, we wanted to investigate the presence of inflammatory mediators and regulators that 
may play a role in prion pathogenesis, including certain analytes (IL-1B, IL-6, TNF-a) which have 
been previously reported in the literature for playing a role in neurodegeneration or 
neuroprotection (Blum-Degena et al., 1995; Campbell et al., 1994; Lindholm et al., 1987; Mogi et 
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al., 1994, Mogi et al., 1996; Tribouillard-Tanvier et al., 2009). Cytokines not only play a role in 
cell signaling and recruitment, but also function in cell proliferation and differentiation. In the 
periphery, the LRS and complement are known to play a role in prion pathogenesis through 
propagation of PrPSc, however, immune responses within the CNS, are much more tightly 
regulated for the obvious reason of limited space to accommodate inflammatory cells. The blood-
brain-barrier (BBB) and additional regulatory mechanisms may cause immune responses in the 
periphery to vary greatly from what is observed in the CNS, therefore separate analysis of these 
immune responses is necessary.  
 
Histopathological findings associated with scrapie infection include spongiosis, neuronal and 
neuropil vacuolation, PrPres, gliosis (Fraser et al., 1988; Jendroska et al., 1991), as well as synaptic 
loss (Budka, 2003). A lack of inflammatory infiltrate of peripheral immune cells during TSE 
infection make studying central immune responses important. Astrocytes and microglia make up 
the two most important cell types contributing to neuroinflammation, as they are stimulated to 
undergo proliferation early on during prion disease (Betmouni, Perry, & Gordon, 1996; Block, 
Zecca & Hong, 2007; Campbell et al., 1994; DeArmond, Kristensson, & Bowler, 1992; Giese et 
al., 1998; Williams et al., 1994; Williams et al, 1997), and both cell types have been shown to 
produce cytokines and have an impact on neuronal survivability (Williams et al., 1994; Kim et al., 
1999; Campbell et al., 1994).   
 
NF-κB is a ubiquitously expressed transcription factor shown to be involved in a number of 
inflammatory processes and stimulated by many different ligands. Within the CNS, these include 
TNF-α, Fas ligand, nerve growth factor (NGF), and secreted amyloid-β (Aβ) precursor protein, 
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resulting in neurotoxic, neuroprotective, and anti-apoptotic effects depending on the stimulus and 
cell type (Mattson & Camandola, 2001). Its involvement in neurodegenerative disorders has been 
studied extensively, and also linked with prion disease pathogenesis (Bacot et al., 2003; Fabrizi et 
al., 2001; Zhou et al., 2008). Stimulation of NF-κB through PrPC-dependent signaling pathways 
and by PrP106-126 has been shown to upregulate pro-inflammatory cytokine gene expression and 
inducible nitric oxide synthase (iNOS) (Lu et al., 2012; Sonati et al., 2013). iNOS is involved in 
immunity acting as a catalyst in the formation of reactive oxygen (ROS) and nitrogen intermediate 
species, such as nitric oxide (NO), through reaction with NADPH oxidase (Barth et al., 2009).  
 
This study represents the first and only to assess cytokine profiles in the serum of the same prion-
infected mice from baseline levels, chronically throughout the delayed onset of disease following 
IP inoculation, until terminal morbidity score warrants euthanasia. Additional sacrifices were made 
at time points leading up to terminal disease (40, 60, and 80dpi) for cross-sectional comparison of 
cytokine profiles present in the brain homogenate of mice prior to prion neuroinvasion (40dpi), 
and afterwards (60dpi—based on previous observations), and were compared with cytokines 
























TgA20 mice (n=31) overexpressing murine PrPC 4- to 10-fold over wild type were genotyped by 
H. Bender and housed at Colorado State University Laboratory Animal Resources (LAR) facility. 
Animals were inoculated IP with 1% brain homogenate of either normal brain homogenate (NBH) 
or Rocky Mountain Laboratories (RML) mouse-adapted scrapie prions, with 1% pen strep in 
sucrose solution. Due to colony breeding problems, mice from this study were inoculated in two 
separate groups but followed identical study design and sample collection procedures. Mice were 
euthanized at 40 (n=6), 60 (n=6), or 80 (n=7) days post inoculation, or once terminal disease was 
apparent (n=12) for cross-sectional brain homogenate cytokine analysis (Figure 3). Morbidity 
scoring was used for impaired extensor reflex, tail rigidity, akinesia, tremors, ataxia, and weight 




Figure 3: Timeline of Longitudinal Cytokine Study 
Schematic of longitudinal cytokine study showing the overall timeline of events as well as the 
numbers of mice starting out and ending the study. Photos show actual IP inoculation of TgA20 
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mice as well as tail bleeding set-up. Additional sacrifices were made at 40, 60, and 80dpi, shown 
by a small brain picture overlapping tail-bleed photos to represent cross-sectional brain 
homogenate cytokine analysis. Mice that were carried out to terminal disease were analyzed for 
serum and brain homogenate cytokine levels as well.  
 
 
Euthanasia and Tissue Harvest:  
At the time of sacrifice, CO2 euthanasia was carried out and the following tissues were harvested 
and immediately frozen at -80°C: mediastinal lymph node; mesenteric lymph node; half spleen; 
and small half of brain (brains cut just off-center). The other half of the spleen and larger half of 
the brain were placed in 10mls of 4% buffered formalin together for 24 hours then transferred to 
70% ethanol until cut into cassettes for histopathology. After allowing 20-30 min for clotting, 
whole blood samples from post-euthanasia heart-stick were centrifuged at 3000rpm for 10 min and 
serum transferred to Eppendorf tubes for immediate freezing with other tissues.   
  
Longitudinal Serum Collection:  
Serum was obtained via tail bleeding per LAR’s mouse bleeding guidelines. One hundred 
microliters of whole blood was collected in BD Microtainer serum separator tubes (ref# 365959) 
and allowed to clot for 20-30 min. Samples were spun down at 3000rpm for 10 min on Micromax 
benchtop centrifuge and serum placed in new eppendorf tubes and stored at -80°C until analysis 
on BioPlex.  
 
LPS-Induction Experiment:  
Two TgA20 mice (1 male, 1 female) negative for PrPres were intraperitoneally injected with 100ul 
of 1μg/ml of LPS (generously provided by Ron Tjalkens’ lab) in PBS. After three hours, both mice 
were euthanized and tissues were collected per above euthanasia protocol. Serum and brain 
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homogenate from LPS-induced mice were analyzed on the BioPlex Suspension Array system as a 





Brains and spleens were cut in coronal sections and GFAP and H&E staining were performed by 
Todd Bass at the CSU Diagnostic Medicine Center.  
 
IHC was done in-house using unconjugated BAR224 for PrPres. Prepared slides were deparafinized 
by heating in an incubator for 45 minutes then exposed to xylene, twice, for 10 minutes each. 
Tissues were rehydrated then digested via a 30 minute, 88% formic acid treatment. Antigen 
retrieval was carried out using 1X Dako Antigen retrieval solution then washed in 1X PBS. 
Quenching was achieved using 3% hydrogen peroxide in MeOH for 30 minutes and were 
subsequently washed and blocked in FACS buffer (5% BSA mixed 1:1 with superblock) for 30 
minutes. Tissues were incubated with unconjugated BAR224 mAb (Cat# 10009035) at 1:500 
overnight and then developed using AEC (3-amino-9-ethylcarbazole) until signal was visualized. 
After another wash, slides were counterstained with hematoxylin, rinsed with tap water, and then 
incubated with bluing reagent for 5 minutes. After a final wash, slides were cover-slipped, 
visualized, and photographed on the Olympus BX41 microscope equipped with Olympus DP72 







Western Blot:  
 
Ten percent brain homogenate from all TgA20 mice in the cytokine study (including LPS mice) 
were Proteinase K-digested at 200µg/ml of recombinant, PCR grade PK (Roche, ref# 03 115 887 
001) for 30 minutes at 37°C at 800rpm on heat block (Eppendorf Thermomixer R). One sample 
(136539-1 RML_M) was left undigested as a control. TgA20 NBH (PK -), the above PK-digested 
samples, and TgA20 RML (used for inoculum—PK+) were loaded onto 12% NuPage 12-well gels 
(10μl undigested, 15μl PK-digested loaded). Ten microliters of 3X loading buffer (Novex NuPage 
LDS 4X sample buffer, ref# NP0007; and 10X reducing agent, ref# NP0009) were added to 
undigested samples (diluted 1:5 in PBS) and to 20μl of digested samples (18ul sample, 2ul PK). 
All samples were then placed on heat block at 95°C for 5min at 800rpm before being loaded onto 
the gels. Samples were run at 110V for 10 minutes, then 150V for 60 min with a Coomassie gel 
marker with BSA to confirm transfer of protein onto membrane. Protein was completely 
transferred onto membrane after 30 minutes at 110V.  
 
Blots were allowed to block for 1 hour in 5% nonfat dry milk + PBS and 0.1% tween before being 
probed with BAR 224 antibody at 1:20,0000 in superblock (Thermo Scientific ref# 37517), in the 
fridge on a rocker overnight. Blots were washed 6X with PBST for 10min each and then developed 
using Millipore HRP Substrate (Immobilon Western, Cat# WBKLS0500). Blots were exposed and 









Sample and Standard Preparation: 
Serum samples were thawed on ice, vortexed for 3-5 seconds, and re-centrifuged at 3000rpm for 
10min. Mouse serum was placed in separate Eppendorf tubes and diluted 1:6—brain homogenate 
1:10—in Universal Assay Buffer (UAB). Serum and brain homogenate dilutions were determined 
via optimization experiments using eBioscience 11-plex kits combined with IL-10 simplex to 
accurately quantitate protein expression in both sample types as well as kit standards. During 
sample centrifugation, cytokine standards (S1-S8) were prepared as 4-fold serial dilution in UAB, 
according to eBioscience protocol. Control wells were comprised of extra reconstituted standard, 
diluted 1:64 to equate S4 and placed at the end of the plate to ensure the assay worked throughout 
entire plate reading.  
 
96-Well Bead Plate Preparation: 
Two U-bottom, untreated, 96-well plates were labeled for either beads or samples (in duplicate). 
Sixty microliters of UAB, S1-S8, samples (up to n=37) and controls were loaded into sample plate, 
for blank, standard, sample (diluted serum/brain homogenate) and control wells, respectively—
this plate was kept on ice until bead plate was prepped. Antibody magnetic bead mixture (11-plex) 
and IL-10 beads were vortexed for 30 sec each prior to being loaded.  Fifty microliters of the 11-
plex bead mixture was loaded into all blank, standard, sample, and control wells (in order of bead 
plate reading). The bead plate was secured onto magnetic plate and beads were allowed to settle 
for two min. Bead plate + magnet apparatus was inverted over sink to decant excess fluid, quickly 
dabbed on paper towel, then returned to benchtop where plate was removed from magnet and 
freshly-vortexed IL-10 beads were added and gently mixed by pipetting. The bead plate was re-
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secured to magnetic plate, allowed two minutes for bead-settling, then washed two times, as 
follows:   
 
Washing Protocol: 
The bead plate + magnet apparatus was inverted over sink to decant excess fluid and then quickly 
dabbed onto paper towel to dry plate surface. Wash buffer (100µl—previously diluted to 1X 
solution) was quickly added to all wells using multi-channel pipette to prevent bead drying. Beads 
were allowed to settle for another 30 sec to 1 min, then the plate was decanted over sink again. 
Wells were washed with 100µl UAB a total of two to three times using the same method as above.  
 
Magnetic Antibody Bead-Sample Incubation:      
Using a multi-channel pipette, 50µl of well contents from sample plate were transferred to bead 
plate, and mixed gently by pipetting. Once all samples were transferred, the bead plate was 
removed from magnet, wells covered with plate cover, wrapped in foil to protect beads from light 
and placed on a plate shaker at room temp for 90 min at 600rpm.  
 
BioPlex Machine, Protocol Setup:  
Protocol details saved for each BioPlex run. Bead regions entered for 11-plex (IFN-g, GM-CSF, 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-12p70, IL-13, IL-18, TNF-a) and IL-10 simplex, per eBioscience 
manual. Standard concentrations calculated using S1 concentration (provided by eBioscience) and 
4-fold serial dilution through S8. Controls matched to S4 concentration (S1 diluted 1:64 for each 
analyte). Details for specific protocol and samples described, and associated dilutions entered (1:6 
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for serum, 1:10 for brain homogenate). One hundred beads per region specified, run at low RP1 
target value settings, with a sample size of 100µl. Gates set at 5000-25,000.  
 
Detection Antibody: 
Following 90 min sample incubation, plate was returned to magnet and left for 2 min prior to three 
plate washes (see washing protocol above). Detection antibody 50X concentrate, for 11-plex and 
IL-10 simplex, each diluted to 1X working solution based off 25µl/well calculation, plus extra to 
account for pipetting error. Detection antibody 1X solution vortexed gently then added in 25µl 
increments to each row using multi-channel pipette. A new plate sealer was placed over wells and 
beads protected from light during 30 min, room-temp incubation on plate shaker at 600rpm. 
 
Streptavidin-PE: 
Plate returned to magnet and washed a total of three times. Total volume of strep-PE estimated 
using 50µl/well calculation. Once plate removed from magnet, 50µl of Strep-PE added to each 
well using multi-channel pipette. Plate re-sealed, protected from light and incubated on plate 
shaker at room temp for 30 min at 600 rpm.  
 
Preparation for BioPlex: 
Plate returned to magnet and washed an additional three times. Once the plate was removed from 
magnet, beads resuspended in 120µl of reading buffer (provided in eBioscience 11-plex kit) and 
plate covered and placed on plate shaker for 1 min at 800rpm. BioPlex machine (warmed-up and 
calibrated prior to plate-reading) ejects calibration plate, and bead plate inserted into BioPlex 
machine for analysis.   
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Statistical analysis:  
A repeated-measure analysis between treatment (TX) groups and over time for IL-2 and IL-5 
performed by Ann Hess in SAS.  Adjusted raw and Tukey p-values were obtained to show 
significant differences over the time course of the study for IL-2 and IL-5. Additional GraphPad 





Monocyte Chemoattractant Protein-1 (MCP-1) expression was quantitated in pooled mouse sera 
via R&D mouse MCP-1 duoset sandwich ELISA (catalog # DY479, Lot# 1320396) performed by 
Dr. Valerie Johnson of Dr. Steven Dow’s laboratory. Due to a limited amount of remaining sample 
volume following BioPlex protein array analysis, mouse sera and brain homogenates from each 
treatment group (NBH males, NBH females, RML males, and RML females) were pooled and 







This novel 3-dimensional brain imaging technique was originally developed by Chung et al. (2013) 
at Stanford University. The CLARITY protocol was carried out as described by Chung et al. and 
adapted by our group to incorporate our immunohistochemistry and other histological staining 
techniques. Briefly, hydrogel monomers (acrylamide and bisacrylamide), formaldehyde, and 
thermally triggered initiators were infused into mouse tissues at 4°C and held at this temperature 
for 1-3 days, allowing for tissue crosslinking and covalent linking between hydrogel monomers 
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and mouse biomolecules (proteins, nucleic acids, etc.). Polymerization of biomolecule-conjugated 
monomers into hydrogel meshwork was thermally-initiated by incubating infused tissue at 37°C 
for 3 hours. Lipids and other molecules lacking functional groups remain unbound, and the 
following electrophoresis step (4 days) allows for tissue clearance of all unbound material. The 
end result is a full or large section brain tissue that is transparent and able to be stained and 
unstained as desired, allowing for visualization of 3-dimensional stain uptake within intact cellular 
architecture (except lipids).  
 
The availability of NFκB-GFP mice, along with development of a new lab protocol for CLARITY 
prompted us to investigate NFκB activation in a RML-infected mouse sacrificed at 60dpi (mouse 
provided by Dr. Val Johnson). For this experiment, we used a 1mm section of brain tissue (to 
expedite the tissue-clearing process) and assessed brain regions expressing GFP using confocal 
microscopy. 
 
CLARITY Imaging- Zeiss Confocal Inverted Scope: 
Argon laser (λ 488) used to visualize a 1mm section of brain from GFP/NFκB mice. DIC channel 
as well as Ch3 LP505 (GFP=530) were turned on for Z-stack. Z-settings: Start:0.300μm; Interval 
10 (Optimal 9.89μm); Pixels 512 X 512; Scan speed 3; DIC scan 5μm. Image of GFP expression 










Four TgA20 mice were euthanized and brains and spleens harvested then placed in 5mls of FACS 
buffer (recipe from Coldspring Harbor: 1 X PBS, 2% FBS, and 1mM EDTA). Organs were mashed 
through cell strainer screen (BD Falcon) and resulting homogenates were placed in Eppendorf 
tubes (500μl for spleens, 200μl for brains). Samples were spun at 3000rpm in IEC Micromax 
benchtop centrifuge for 5 minutes. Supernatant was removed and pellet was washed in 1ml FACS 
buffer. Samples were then subjected to a soft centrifugation at 1000rpm for 5 minutes.  Wash and 
soft spin (1000rpm for 5 min) was repeated two times.  
 
Cells were FC blocked at 1:100 FC block in FACS buffer for 30 minutes. Cells were washed twice 
then incubated with BAR224 antibody at 1:100 with 7% mouse serum in FACS buffer for 20 
minutes in the dark at room temp. Excess antibody was washed away using 1ml FACS buffer, 
followed by a soft spin. Lysis buffer (155mM NH4Cl, 12mM NaHCO3, and 0.1mM EDTA) was 
used in place of FACS buffer for the final wash. Cells were centrifuged one final time, supernatant 
disposed of, resuspended in 1ml FACS buffer, transferred to library tubes, and kept in the dark 
until analysis on the Cyan Flow Cytometer at the Colorado State University, Veterinary Teaching 















Mice were euthanized at 40dpi, 60dpi, 80dpi, or when prion disease morbidity scores indicated 
terminal illness (Table 1). RML-female mice reached terminal illness and were euthanized prior 
to the first RML-male who showed any clinical symptoms (Figure 4). NBH control mice were 
allowed to survive out to 158dpi for the terminal time point and no clinical signs of prion disease 
were apparent at the time of euthanasia (see appendix for supplementary URL link to YouTube 
videos). 
Table 1: Cytokine Study TgA20 Information Table 
TgA20 mice from the longitudinal cytokine study are separated by euthanasia time point to show 
the division of treatment groups and genders of mice, as well as ages at the time of inoculation and 
euthanasia. Mice were euthanized at 40dpi (average age of 154 days old), 60dpi (averaging 160 
days old), 80dpi (averaging 178 days old), or when terminal illness became apparent. NBH control 
mice for the terminal time point were allowed to live 14 days past the euthanasia of the RML-
inoculated mouse, 134097-3, which had the longest incubation period for the RML treatment 
group. 
Cytokine Study TgA20 Information Table 
Animal ID TX Group Gender Age at 
Inoculation 
(days) 
Age at euth 
(days) 
DPI @ euth Incubation Period 
(days to terminal 
illness) 
133157-5 NBH M 103 145 40 n/a 
136540-1 NBH F 117 159 40 n/a 
136539-2 RML M 117 159 40 n/a 
136539-3 RML M 117 159 40 n/a 
136550-3 RML F 110 152 40 n/a 
136550-4 RML F 110 152 40 n/a 
133157-4 NBH M 103 163 60 n/a 
136540-2 NBH F 117 177 60 n/a 
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133707-4 RML M 92 152 60 n/a 
134097-1 RML M 77 137 60 n/a 
135588-2 RML F 103 163 60 n/a 
136550-1 RML F 110 170 60 n/a 
133157-3 NBH M 103 183 80 n/a 
133158-5 NBH F 103 183 80 n/a 
133707-1 RML M 92 172 80 n/a 
133707-2 RML M 92 172 80 n/a 
134098-1 RML F 77 157 80 n/a 
135588-4 RML F 103 183 80 n/a 
136550-2 RML F 110 193 80 n/a 
134098-3 RML F 77 177 100 100 
134098-5 RML F 77 177 100 100 
134098-4 RML F 77 188 111 111 
134098-2 RML F 77 193 117 117 
134097-2 RML M 77 197 120 120 
136539-1 RML M 117 238 121 121 
134097-4 RML M 77 205 128 128 
134097-3 RML M 77 220 144 144 
133157-1 NBH M 103 260 158 n/a 
133157-2 NBH M 103 260 158 n/a 
133158-1 NBH F 103 260 158 n/a 
133158-3 NBH F 103 260 158 n/a 
141158-1 LPS M n/a 114 n/a n/a 






Figure 4: Kaplan-Meier Survival Curve of Cytokine Study TgA20 Mice 
Kaplan-Meier survival curve generated using Prism software (version 5.0d). RML-Males and 
RML-females were euthanized when prion disease morbidity score indicated terminal illness. 
NBH animals were euthanized at 158dpi with no outward signs of prion disease. RML-females 
were euthanized an average of 107dpi, whereas RML-male mice averaged 128dpi with no overlap 






Western blot confirmed the presence of PK-resistant material in brain homogenate from RML-
inoculated mice at 60dpi, 80dpi and at terminal disease (Figure 5, A&B). The absence of PrPres at 
40dpi confirms our hypothesis that RML-prions, when inoculated IP, do not enter the brain until 
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Figure 5 (A & B): Western Blots of TgA20 Brain Homogenate from Longitudinal Cytokine 
Study 
TgA20 NBH - negative for prions - was included in well 1 on both blots as a representative of 
undigested negative brain material and TgA20 RML was loaded into well 12 on both blots as a 
positive control. (A) 10% brain homogenate from NBH-inoculated animals is shown in wells 2-6 
and RML-inoculated animals in wells 8-11 in the order of 40dpi, 60dpi, 80dpi and terminal. Well 
7 was left blank to prevent sample spill-over. (B) NBH-inoculated brain material from each time 
point is shown in wells 2-5 and RML-inoculated animals from each time point are shown in wells 
7-10. Well 11 shows undigested brain material from RML-infected mouse 136539-1, whose PK-






Cytokine levels for GM-CSF, IFN-γ, IL-1β, IL-4, IL-6, IL-12p70, IL-13, IL-18, TNF-α, and IL-
10 were overall below detection limit (out-of-range low, OOR<), set by the lowest value from the 
standard curve. IL-2 and IL-5 showed the most robust and consistent signals throughout the 
longitudinal study, with a few mice showing pro- and/or anti-inflammatory cytokine responses at 
varying time points (see Appendix, Table 1A—Supplementary, Cytokine Mega Table). A 
repeated-measure statistical analysis using SAS revealed that although no significant differences 
were observed between the RML and NBH treatment groups, there was a significant difference 
over time for IL-2 and IL-5 (Table 2). Due to unequal numbers between treatment groups and 
numerous OOR< values, a repeated measures analysis could not be performed using SAS for the 
other cytokines. In an attempt to overcome this issue, and not miss other significant differences 
between genders, treatment groups and time for other analytes, cytokine data was bootstrapped to 
fill in missing values and a repeated measures two-way ANOVA was performed using Prism 
software (version 5.0d). This secondary statistical analysis revealed a number of additional 
significant differences for the other cytokines, as well as confirmed the statistical significance seen 




Table 2 (A - D):  
Results of SAS analysis (repeated measures performed by Ann Hess). Tables 2A and 2B pertain 
to IL-2, and tables 2C and 2D pertain to IL-5. Tables 2A and 2C show maximum and minimum 
(usually <OOR) observed cytokine concentration (pg/ml) along with mean and standard deviation 
for longitudinal data. Tables 2B and 2D show p-values associated with factors that were analyzed, 
such as gender, time, treatment groups, etc.  
 
Table 2A: IL-2 SAS Statistical Analysis 
At 20dpi, the observed serum concentration of IL-2 peaks for both NBH and RML treatment 




DPI N Obs Mean Std Dev Minimum Maximum 
NBH 0 10 2.827 5.836 0.140 16.550 
 1 10 8.044 8.378 0.080 23.880 
 20 10 24.369 18.920 0.080 51.160 
 40 10 11.375 10.503 0.080 26.180 
 60 8 11.109 11.365 0.090 31.490 
 80 6 14.940 6.623 7.520 23.500 
 Term 4 0.085 0 0.080 0.085 
RML 0 21 4.973 9.779 0.080 41.030 
 1 20 12.689 11.176 0.080 31.120 
 20 21 21.014 18.154 0.090 63.950 
 40 21 14.132 11.278 0.090 37.920 
 60 17 11.278 9.132 0.085 27.020 
 80 13 12.237 11.195 0.085 30.420 
 Term 8 2.696 6.092 0.080 17.460 
 
Table 2B: IL-2 SAS Type 3 Tests of Fixed Effects 
IL-2 was only shown to have a significant differences over time (p-value <0.0001), but not for any 
other interactions.   
 
Effect F Value Pr > F 
Gender 0.06 0.8010 
TX_Group 0.12 0.7277 
Gender*TX_Group 0.33 0.5703 
DPI 9.48 <0.0001 
Gender*DPI 0.61 0.7220 
TX_Group*DPI 0.73 0.6285 








Table 2C: IL-5 SAS Statistical Analysis  
Similar to IL-2, IL-5 peaked at 20dpi for the NBH animals, whereas the peak was observed at 




DPI N Obs Mean Std Dev Minimum Maximum 
NBH 0 10 1.893 2.351 0.300 7.190 
 1 10 8.009 10.341 0.305 27.970 
 20 10 5.143 8.680 0.305 29.180 
 40 10 7.457 7.389 0.220 27.200 
 60 8 4.151 5.944 0.220 17.330 
 80 6 1.227 1.587 0.210 3.570 
 Term 4 2.780 1.858 0.210 4.590 
RML 0 21 1.532 2.044 0.210 7.190 
 1 20 2.828 3.553 0.210 12.800 
 20 21 4.153 5.527 0.210 20.730 
 40 21 4.903 5.355 0.210 22.770 
 60 17 4.405 3.960 0.210 16.650 
 80 13 3.115 3.333 0.210 10.170 
 Term 8 3.279 4.834 0.210 13.230 
 
 
Table 2D: IL-5 SAS Type 3 Tests of Fixed Effects 
IL-5 showed significant differences between males and females (p-value 0.0021), as well as a 
statistically significant variation over the course of disease (p-value 0.0016).  
 
Effect F Value Pr > F 
Gender 11.19 0.0021 
TX_Group 1.29 0.2647 
Gender*TX_Group 0.14 0.7061 
DPI 4.30 0.0016 
Gender*DPI 1.07 0.3961 
TX_Group*DPI 1.07 0.3941 














Table 3: Repeated Measures Two-Way ANOVA of Cytokine Data  
Two-way ANOVA repeated measures analysis performed using PRISM software (version 5.0d) 
on bootstrapped cytokine data. IL-2 and IL-5 significance over time was reconfirmed using this 
method of statistical analysis with IL-2 having a p-value of <0.0001 (same as SAS analysis), and 
IL-5 also at <0.0001 (compared with 0.0016 on SAS). Additionally, IL-6, TNF-α, and IL-18 were 
shown to have significance over time, IFN-γ and IL-5 were significantly different between 
treatment groups, and IL-5, IL-6, and TNF-α had statistically significant interactions between 
treatments and time.     
 
Cytokine Significant Trends        
(p-value) 
Significant DPI 
IFN- Treatment* (0.0286) n/a 
IL-2 Time**** (<0.0001) Baseline to 20dpi: NBH 
Males**** (<0.0001),  
NBH Females* (<0.05), RML 
Males*** (<0.001)  
 
20dpi to Terminal: NBH 
Males**** (<0.0001),  
NBH Females**** (<0.0001), 
RML Males ****  
(<0.0001) 
IL-5 Interaction** (0.0029) 
Treatment*** (0.0005) 
Time**** (<0.0001) 
NBH Females 1dpi** (<0.01), 
80dpi** (<0.01) 
IL-6 Interaction* (0.0344) 
Time** (0.0021) 
NBH Females 40dpi*** 
(<0.001) 
IL-18 Time *** (0.0003) n/a 
TNF- Interaction** (0.0019) 
Time* (0.0130) 
NBH Females 1dpi**; NBH 
Males 40dpi*  











































































































































TgA20 mice overexpress PrPC in the CNS at reported levels of 4- to 10-fold higher than wild type 
mice. We performed an experiment utilizing flow cytometry to determine whether peripheral PrPC 
expression level correlated to the higher expression level seen in the CNS. If PrPC expression is 
much lower in the spleen—an organ known to play an important role in peripheral prion replication 
and propagation as well as immunity—then the overall cytokine expression could be altered and 
may influence downstream effects in disease progression and resulting pathology. Since PrPC is 
required for prion-associated neuronal death, expression level in the periphery versus the brain 
could directly affect cellular signals of neurotoxicitiy/neuroprotection and ultimately cellular 
survival. In order to investigate this, we euthanized four TgA20 mice—two males and two 
females—and analyzed filtered brain and spleen homogenates tagged with PE-Texas Red and 
antibody-probed for PrPC. Cells were analyzed via flow cytometry and the percent of PrP-
expressing cells from brain and spleen homogenates was determined using mean fluorescence 
intensity (MFI).  
 
We found that males showed slightly higher PrPC-expression in both the brain and the spleen over 
females, although this difference was subtle (Figure 13).  Interestingly, we observed PrPC 
expression levels 20-fold higher in the brain than the spleen in TgA20s (Figure 13, C & D).  















Figure 13 (A-D): Flow Cytometry Characterization of PrPC Expression Levels 
Four age-related TgA20s, two male (M1 & M2) and two female (F1 & F2) were euthanized and 
brains and spleen homogenates were stained for PrPC and quantitated by flow cytometry. (A) 
Levels of PrPC(+) splenic cells compared to unstained (Spl Un) in grey. (B) Levels of PrPC(+) 
brain cells compared to unstained (Un Br) in grey. (C) Overlap of Figure 13, A & B with spleen 
represented in red and brain in grey, solid background correlates to unstained. (D) Graphical 






Overall, MCP-1 levels in the serum of study animals are lower in prion-infected animals, with 
animals from both treatment groups displaying low levels compared to LPS-induced positive 
control mice. Whereas in the brain, MCP-1 levels from RML male mice increase above the levels 
seen in LPS-controls. Likely due to a single mouse which showed chronic, significantly increase 













Figure 14 (A & B): MCP-1 ELISA in serum (A) and brain (B)  
Pooled samples due to limited volume show lower MCP-1 expression in the serum of RML-
infected mice compared to NBH, but both were significantly below LPS average (A). MCP-1 in 
the brain homogenate from RML males is exceptionally high (B), likely due to the chronic 
inflammation from expression of other pro-inflammatory cytokine signals apparent in a single 






Histological staining techniques are often used for assessing prion-induced neuropathology and 
include immunohistochemistry for PrPres and H&E stain for neuronal vacuolation and spongiosis. 
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein encoded by the GFAP 
gene. Within the CNS, GFAP is expressed during reactive gliosis and is mostly associated with 





Figure 15 (A-C) shows IHC staining of PrPres material in mice sacrificed at 80dpi and at terminal 
disease. Staining for GFAP and H&E for spongiosis yielded unexpected results, showing mild 
vacuolation in both RML- and NBH- inoculated mice (pictures not shown), with atypical GFAP 
staining in the hypothalamus and caudal medulla region, ventral to the cerebellum at the level of 
the cerebellar peduncles and lateral cerebellar nuclei (Figure 16).     
 







Figure 15: IHC for PrPSc in the brains of mice infected with RML mouse-adapted scrapie 
IHC + staining in RML-infected female mouse sacrificed at 83dpi in the hypothalamus near the 
3rd ventricle (A) and in the region of the cerebellar peduncle (B), coinciding with the region where 
higher intensity GFAP staining was observed. PrPres was also detected in and surrounding the 3rd 
































Figure 16, A-D: GFAP Staining in NBH- and RML-Inoculated TgA20 Mouse Brains 
A & B show GFAP stain uptake in caudal medulla of NBH-inoculated male and female mice, 
respectively. This diffuse, light staining is indicative of normal, low-level astrogliosis present in 
overexpressing mouse models. Compared to figures C and D, which display darker, heavier GFAP 
staining with occasional “hotspots” in RML-inoculated mice. This stain pattern is suggestive of 
more extensive astrogliosis in prion-infected animals, in spite of overall low-level PrPSc 





Due to IHC/GFAP/H&E histologic findings that were atypical for naturally-occurring and other 
experimental models of prion disease, we investigated the activation of the NFκB transcription 
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factor in GFP-NFκB expressing mice infected with RML and euthanized at 60dpi. We used a 
newly-developed CLARITY protocol to clarify intact whole sections of mouse brains, ridding 
them of lipid content following crosslinking of proteins and cytoskeletal elements, allowing for 3-
dimensional visualization of GFP expression where NFκB activation was present. Using confocal 
microscopy, we found the only significant GFP expression within the region of the caudal medulla 
underlying and extending into the cerebellum (Figure 17).  
 
 
Figure 17: CLARITY brain section from NFκB-GFP mouse  
Confocal microscopy of a 60dpi scrapie-infected GFP-NFκB mouse showed GFP expression in 








Prion diseases are characterized by a state of progressive and invariably fatal neurodegeneration 
manifesting as cognitive decline and chronic wasting. Prions are misfolded, infectious, 
proteinaceous particles that break the biological dogma of what we understood of transmissible 
disease prior to their discovery (Prusiner, S., 1982). In the normal cellular form, the prion protein 
appears to be ubiquitous among mammals with highly conserved primary biochemical structure 
(Krakauer et al., 1998; Schätzl et al., 1995). High PrPC homology, auto-conversion to 
pathogenicity, and striking environmental persistence of prions in the face of common 
decontamination methods would suggest widespread distribution and a high prevalence of disease 
among host species—however, naturally-occurring prion diseases seem to maintain host-
specificity (Gajdusek, D., 1977), with certain mammalian species showing complete resistance to 
prion-induced neurodegeneration (Bartz et al., 1994; Diaz-San Segundo et al., 2006; Lysek et al., 
2005). The low prevalence of “naturally-occurring” human prion diseases is evidenced by a one-
in-a-million chance of developing sCJD. Naturally-occurring animal prion diseases, however, are 
a larger problem with historical reports of scrapie extending back to the 1700s and a new 
emergence of CWD in North American cervid populations. The distribution of CWD continues to 
expand, along with environmental contamination, and current studies are underway revisiting the 
zoonotic potential of both scrapie and CWD prions (Saunders, Bartelt-Hunt, & Bartz, 2012). It is 
difficult to ascertain the risk factors involved with the consumption of CWD positive brain or 
peripheral tissues from hunter-killed deer, elk, and moose when so much remains unknown about 




The outbreak of BSE in the UK heightened our awareness of the unknowns of prion disease and 
stands as an important reminder that species barriers in prion disease transmission are not well 
understood (Billeter et al., 1997). Additionally, recent comparisons between prion disease and 
other “proteinopathies” such as AD, Parkinson’s, ALS, traumatic brain injury (TBI), and dementia 
provide helpful insight into cellular and molecular pathways that potentially cause disease. In the 
absence of informative genetic material, little is known about the structure and function of PrPSc, 
making the studies of prion epidemiology and pathogenesis challenging—other factors potentially 
involved in prion propagation between different host species become an appealing focus. This 
study recognizes lymphoid involvement as a key feature unique to specific prion diseases and 
quantitated cellular immune signaling molecules in the same animals throughout their disease to 
expose information pertinent to prion disease mechanisms.  
 
A number of past studies have described neuroinflammation involved in neurodegenerative 
processes. In AD it is thought that expression of pro-inflammatory cytokines such as IL-1β, IL-6, 
IFN-γ, and TNF-α contribute to astrocytosis and exacerbate neuronal oxidative stress through the 
production of NO through the iNOS pathway (Chiarini et al., 2005; Eikelenboom et al., 1994, 
McGeer & McGeer, 1995; Sudduth et al., 2013). Chiarini et al. further characterized this signaling 
and found that cytokines themselves were mildly neurotoxic, but when combined with the presence 
of Aβ the neurotoxic effect significantly increased. Their group also looked at the involvement of 
p75, a neuronal cell surface receptor in the same family as other death receptors, which has been 
shown to bind both Aβ and NGF (Lu et al., 2005; Nagata et al., 1997; Smith et al., 1994). It was 
determined that Aβ-p75 binding can in fact induce cell death through generation of ROS (Chiarini 
et al., 2005). Within a murine scrapie model, it was demonstrated that IL-1 is a significant inducer 
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of astrogliosis, and IL-1-/- mice had prolonged incubation periods (Schultz et al., 2004). However, 
they also noted increased microgliosis in the murine IL-1-/- model and progression to terminal 
disease in the absence of IL-1.  
 
Histopathological findings associated with scrapie infection include spongiosis, neuronal and 
neuropil vacuolation, PrPres, gliosis (Fraser, 1988; Jendroska et al., 1991), as well as synaptic loss 
(Budka, 2003). A lack of inflammatory infiltrate of peripheral immune cells during TSE infection 
makes studying central immune responses represented by cytokines important. Astrocytes and 
microglia make up the two most important cell types contributing to neuroinflammation, as they 
are stimulated to undergo proliferation early on during prion disease (Betmouni, Perry, & Gordon, 
1996; Campbell et al., 1994; DeArmond, Kristensson, & Bowler, 1992; Giese et al., 1998; 
Williams et al., 1994; Williams et al, 1997), and both cell types have been shown to produce 
cytokines and have an impact on neuronal survivability (Campbell et al., 1994; Kim et al., 1999; 
Williams et al., 1994).  Microgliosis co-localizing with areas of pathology (i.e. PrPres deposition 
and/or vacuolization) is commonly observed in CJD brains and murine scrapie models (Sasaki, 
Hirato, & Nakazato, 1993; Williams et al., 1994).  
 
Other groups have reported that the typical pro-inflammatory cytokine profile was not observed in 
certain prion disease models, as was the case for the ME-7 form of murine scrapie (Cunningham, 
Boche, & Perry, 2002; Walsh, Betmouni, & Perry, 2001). Studies in this animal model show a 
preponderance of TGF-β1 expression, which can directly down-regulate iNOS (Minghetti & Levi, 
1998). While we were interested in the possibility of anti-inflammatory cytokine expression, the 
unstable nature of TGF-β prompted us to, instead, analyze IL-10 in the multiplex assay. Multiple 
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investigators have demonstrated involvement of TGF-β and IL-10 in prion disease models (Baker 
et al., 1999), as both TGF-β and IL-10 negatively impact cytokine expression from microglia in 
vitro (Lodge & Sriram, 1996). Additionally, it has been shown that IL-10 can down-regulate IL-
1β and TNF-α (Bogdan et al., 1992; Chao et al., 1995; Lodge & Sriram, 1996). 
 
It should be noted that specific cytokine expression and cellular pathways vary depending on 
disease, genetic factors, PrP expression level, and chosen experimental animal model. For 
example, oxidative stress and apoptotic pathways are a known component of AD pathogenesis and 
other protein-misfolding disorders. The cytokine profiles and mechanisms of neuronal death are 
less clear for prion-induced TSEs, but may also involve apoptotic pathways (Giese et al., 1995; 
Williams et al., 1997). The findings from this study cytokine variations possibly relevant to the 
physiologic role of PrPC and unveil a distinctive neuropathological profile that may provide clues 




A repeated measures statistical analysis revealed significant differences for both IL-2 (p-value 
<0.0001) and Il-5 (p-value 0.0016) over time for the longitudinal cytokine data (Table 2, A-D). 
However, no significant difference was observed between treatment groups throughout the disease 
for these two cytokines, suggesting that either the TgA20 transgenic mouse model or over-





Interleukin-2 acts as a T cell growth factor in an autocrine manner to induce proliferation and 
activation of T lymphocytes. The consistent expression of IL-2 throughout the longitudinal study 
in both infected and uninfected mice is somewhat surprising, as the involvement of T cells in prion 
pathogenesis appears to be non-essential (Klein et al., 1997). Disease progression and incubation 
periods in prion-infected SCID mice, a strain devoid of functional B and T cells (Bosma et al., 
1983) as well as FDCs (Szakal et al., 1990), show resistance to murine CJD through peripheral 
route of inoculation (Kitamoto et al., 1991).  
 
Another hypothesis relating IL-2 expression to the TgA20 transgenic model involves the location 
of the insertional transgene for Prnp. Zabel et al. (2009) characterized the immune composition of 
lymphocytes in PrPC-expressing transgenic models at 0- (PrP-/-), 1- (wild-type), 3-5 (Tg19), and 
4-7- (TgA20) fold higher than wild-type and found an altered T lymphocyte phenotype in TgA20 
over-expressing mice. Their TgA20s showed a lower number of αβ(+) T cells compared to γδ(+) 
T cells, reflected in overall lower numbers of CD4 and CD8 T cells. Despite an atypical T 
lymphocyte phenotype, the normal 2:1 ratio of CD4+:CD8+ T cells remained and T cell function 
was not compromised. It was suggested that this is due to the Prnp transgene insertion centrally 
within murine chromosome 17, a location correlated to a number of genes involved in T cell 
development (Fehling et al., 1995; Havelkova et al., 1999).  TgA20 mice have reduced TCR 
mRNA transcript and protein, which has been shown to induce expression of the high affinity IL-
2receptor (Kim & Leonard, 2002).  Failure to up-regulate IL-2R could cause increased 




Interleukin-2 is multifunctional and displays roles extending beyond T lymphocyte activation and 
proliferation. In fact, within the rat brain IL-2 is expressed, with the highest concentration of its 
binding sites localized to the hippocampal formation (Arujo et al., 1989; Lapchak & Hefti, 1991; 
Nieto-Sampedro & Chandy, 1987). Within the brain it is proposed that IL-2 contributes to 
elongation and branching of neurites and positively effects neuronal survival in a dose-dependent 
fashion (Awatsuji et al., 1993; Sarder, Saito, & Abe, 1993; Sarder et al., 1996; Shimojo et al., 
1993). This effect was blocked when anti-IL-2 antibodies were added (Awatsuji et al., 1993). 
Although IL-2R may be most concentrated in the hippocampal formation, Awatsuji et al. (1993) 
proved IL-2 to have similar effects on cortical, septal, and striatal neurons. Importantly, IL-2 
appears to be involved in spatial learning and memory, as well as hippocampal neurodevelopment 
(Petitto et al., 1999). 
 
It is clear that IL-2 plays a crucial role in neuronal survivability and neurite elongation and 
branching, promoting spatial learning and memory. However, the current findings from this study 
demonstrate consistent IL-2 expression in both NBH- and RML- inoculated TgA20s, perhaps 
suggesting a correlation between IL-2 and the over-expressed PrPC protein. It has been 
documented that PrP-/- mice show impaired T cell activation and proliferation in response to 
mitogens, compared with PrP +/+ mice (Bainbridge & Walker, 2005). PrPC has also been 
implicated in human lymphocyte activation (Cashman et al., 1990). T lymphocytes may not be 
essential for prion disease progression, but Prnp -/- mice inoculated with rα-PrP or rβ-PrP 
exhibited proliferation of T cells and appear to recognize the same epitope (Khalili-Shirazi et al., 
2005). It was mentioned that the observed proliferation was weak, however, because PrP 
expression plays a role in T cell activation it could be that proliferation was dampened in the 
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knockout model. PrPC is significantly upregulated on the surface of T cells stimulated with 
concanavalin-A, while PrP-/- mice display a reduction in PrPC upregulation, further supporting the 
idea that PrPC participates in T cell activation (Mabbott et al., 1997). This group also observed the 
importance of the GPI anchor of the prion protein in this process.  Ingram et al. (2009) found that 
activated T cells in PrP-/- mice displayed a significant reduction in Th1, Th2, and Th17 cytokine 
expression levels, although others such as TNF-a and IL-9 were unchanged. It could be that the 
opposite is true in this study, and the over-expression of PrPC in TgA20s altered T lymphocyte 
phenotype, as well as increased cytokine expression for IL-5 and/or IL-2.  
 
Interleukin-5 expression showed a significant variation over time (p-value 0.0016), as well as 
between genders (p-value 0.0021) (Table 2, C & D), perhaps suggesting a role for IL-5 in sex-
related differences in prion pathogenesis. Figure 4 from the current study shows terminal clinical 
illness and morbidity scores warranting euthanasia in RML-infected female mice prior to onset of 
apparent clinical symptoms in any of the male RML-infected mice. Within the literature, reports 
of IL-5 acting independently are extremely limited, as it is usually co-expressed with IL-4 in a Th2 
immune response to allergens and parasites. Within a prion disease model, a Th2 immune response 
in PrP-/- mice inoculated with rα-PrP showed IL-5 and IL-10 expression, whereas inoculation of 
rβ-PrP induced a Th1 response shown by IFN-γ (Kahlili-Shirazi et al., 2005). More importantly, 
IL-5 is involved in B-cell growth and proliferation (Takatsu, K., 1998) and may have a relevant 
function in the induction of nerve growth factor (NGF) synthesis/secretion in astrocytes (Awatsuji 
et al., 1993)—the former possibly involved in B cell stimulation of FDCs, an immune cell under 
significant investigation for its proposed role in prion protein propagation within the LRS prior to 
neuroinvasion (Fraser et al., 1989; Fraser et al., 1996; Fraser & Farquhar, 1987). 
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FDCs play a key role in stimulation and viability of memory B cells through antigen presentation 
on the cell surface via CR21/CR35, in contrast to internalized antigens that are processed for T 
cell activation (van Nierop & de Groot, 2002). Within the scope of prion disease, FDCs express 
the prion protein at high levels compared to other immune cells and are an essential component of 
peripheral prion propagation (Brown et al., 1999, McBride et al., 1992). PrPC has been shown to 
co-localize with FDCs in lymph node germinal centers (Kitamoto et al., 1991; McBride et al, 1992; 
Muramoto et al, 1992) and accumulation of the abnormal prion protein is diminished in the spleens 
of mice lacking functional FDCs (Montrasio et al., 2000). Normal maturation of FDCs is 
dependent upon normal functioning B lymphocytes, but interestingly PrPC expression is only 
required on FDCs to sustain peripheral prion replication and initiate neuroinvasion (Klein et al, 
1998; Montrasio et al, 2001). B lymphocytes provide TNF-α and lymphotoxins (LTα and LTβ) as 
required signals for FDC development and maintenance within lymph node germinal centers and 
splenic white pulp (Alimzhanov et al., 1997; Koni et al., 1997; Matsumoto et al., 1997; Montrasio, 
2000). This is supported by the fact that down regulation of the LTβ-R reduces prion pathogenesis 
(Mabbott et al., 2000; Mabbott et al., 2003; Montrasio et al., 2000) and FDCs in an autoimmune, 
chronic-inflammatory disease state resulted in prion detection and replication in atypical organs 
where PrP-expressing FDCs were found, such as the kidney, pancreas, and liver (Heikenwalder et 
al., 2005). Prinz et al. (2002) demonstrated the necessity of B cell follicles for successful FDC-
associated prion replication, and later, that KO of the CCR5 chemokine placed FDCs in closer 
proximity to arterioles and nerves, resulting in accelerated prion neuroinvasion in WT and CCR5-
/- mice (Prinz et al., 2003). B cells were also found to comprise the majority of prion-bearing cells 
within lymph nodes early after IP infection with prions, suggesting an important role in intranodal 
prion trafficking to FDCs (Michel et al., 2013).  Therefore, B lymphocytes are crucial players in 
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peripheral prion replication (Klein et al., 1997) through interdependence with FDCs, and altered 
B cell or FDC development/function can affect prion pathogenesis (Brown et al., 1999; Fraser et 
al., 1996; O’Rourke et al., 1994; Prinz et al., 2002; Prinz et al., 2003).   
 
While it has been shown that IL-4 and IL-5 induce the synthesis and secretion of NGF, this did not 
have any positive effect on neuronal survivability (Awatsuji et al., 1993). NGF has many functions 
pertaining to neurons within the CNS, but one function that may be pertinent to prion-induced 
disease is the induction of B cell growth and differentiation (Otten, Ehrhard, & Peck, 1989). This 
same group also identified the presence of functional NGF receptors on B and T lymphocytes. 
Adding to this idea is the finding that T cell-derived B cell growth factors (i.e. cytokines produced 
by T cells that stimulate B cell growth) induce astrocytic proliferation and GFAP expression 
(Benveniste et al., 1989) in response to cytokines IL-1 (Otten et al., 1989) and IL-6 (Frei et al., 
1989) and possibly others. This is likely through NF-κB activation from cytokine signal 
transduction. Interestingly, NGF may be expressed following activation of certain T-helper 
subtypes (Ehrhard et al., 1993), and it has been shown that NGF stimulates expression of IL-2R, 
and vice versa (Brodie & Gelfand, 1992). If PrPC overexpression in TgA20s is responsible for 
constant IL-2 and IL-5 expression, positive signals sent to B and T cells directly from the above 
cytokine signaling pathways and indirectly through NGF expression may result in up-regulation 
of PrPC in the immune cell compartment (Mabbott et al., 1997; Wion et al., 1988) and over 
stimulation of FDCs, promoting prion propagation. PrPC-mediated cytokine-induction could 
potentially be activating NF- κB as well as up-regulating NGF, but whether the overall effect of 
this activation is anti-apoptotic (Mattson & Camandola, 2001) or cytotoxic through p75 signaling 
and generation of NO (Chiarini et al., 2005) is unknown. The fact that this transgenic model shows 
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expedited disease in the presence of scrapie prions suggests that possibly these cell signaling 




There are mixed reports about the level of PrPC-overexpression in the TgA20 mouse model 
(Fischer et al., 1996; Zabel et al., 2009) and as to whether this level of overexpression is observed 
equally in brain and lymphoid compartments. Flow cytometry of spleens and brains from TgA20 
male and female mice revealed a 20-fold increase of PrPC expression in the brain over what was 
observed in the spleens of these mice (Figure 13). While this finding contradicts PrPC expression 
patterns reported by others (Glatzel & Aguzzi, 2000), we hypothesize that peripheral cytokine 
levels may have been influenced by PrPC-expression in the periphery of TgA20s more similar to 
that of wild-type mice. If this is true, then a decreased inflammatory state in early stages of disease 
in the LRS may have affected overall prion pathogenesis, including neuroinvasion and 




Prion diseases have a complex diagnosis, involving clinical signs, sensitive  and time-consuming 
lab assays (western blot and protein-misfolding cyclic amplification, PMCA) of contaminated 
tissues or fomites, immunohistochemical detection of insoluble, partially PK resistant prion protein 
deposits—both ante mortem and post mortem via lymphoid biopsy, or brain IHC/H&E, 
respectively—or combinations of these. Unfortunately no in-house or field rapid detection assay 
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exists with a high efficacy for ante mortem diagnosis. Neurohistopathology is useful for detection 
of the prion protein within brain tissue and to visualize neuronal vacuolation and spongiosis. 
Attempts to classify clinical and histological characteristics of IHC and other special stain-uptake 
patterns in human CJD have been published (Budka et al., 1995; Parchi et al., 1999) but are 
complicated by many different disease manifestations (Gambetti et al., 2003; Kong et al., 2004; 
Monari et al., 1994).  Similarly, in experimental prion models, disease characteristics are skewed 
by the genetics of the animal model, transgenes, type and strain of prion inoculum, number of 
serial passages within endogenous/exogenous host, dose, and inoculation site/route. For example, 
murine scrapie strain ME7 inoculated intracerebrally into C57BL and VM/Dk mice showed PrP 
accumulation within the hippocampus as the first indicator of neurodegenerative disease (Jeffrey 
et al., 2001), whereas infection with 87V murine scrapie caused vacuolation primarily concentrated 
to the brainstem (Jeffrey et al., 1997).  
 
The findings in this study showed minimal vacuolation and PrPSc-deposition in the region of the 
caudal medulla of terminally ill, RML-infected TgA20s. IHC staining for PrPSc in RML-infected 
animals was in the region of hypothalamus near the 3rd ventricle and in the cerebellar peduncle 
(Figure 15). The most prominent finding supporting “hallmark” characteristics of prion-induced 
neuropathology was (+)GFAP staining in brain regions coinciding with PrPSc deposition and at a 
considerably higher intensity than in NBH TgA20s, but the extent of overall astrogliosis 




The presence of PK-resistant scrapie prions in the brain homogenates of RML-infected mice were 
confirmed by Western blot (Figure 5, A & B), and the presence or absence of clinical disease 
warranting terminal morbidity scores in RML- or NBH- infected animals, respectively, was 
documented on video and uploaded to the laboratory’s private YouTube library (see appendix for 
URL).  
 
Other prion researchers have documented cases of atypical histopathology in various disease 
models, with similar findings of low PrPres concentration, vacuolation and/or astrocytosis (Hegde 
et al., 1998; Hsiao et al., 1994; Jeffrey et al., 2001, Lasmezas et al., 1996; Lasmezas et al., 1997; 
Sisó et al., 2002). Furthermore, a number of papers exist supporting our observed lesion profile, 
involving the cerebellum, brainstem, and/or spinal cord in both natural (Parchi et al., 1999; Wood 
& Done, 1992) and experimental (Baringer et al., 1983; Glatzel & Aguzzi, 2000; Sisó et al., 2002; 
Tamgüney et al., 2009) prion disease models. However, there are different theories as to why this 
observation occurs.  
 
It is difficult to characterize the differences in disease caused by an agent that is a misfolded host-
encoded protein, lacking nucleic acids. While many researchers have recognized prion “strains” 
by variations in clinical signs, incubation period, neuropathology, and deposition patterns of PrPSc 
within host tissues, it is generally accepted that these variations are caused by differences in host 
genetics of Prnp and the biochemical conformation of PrPSc (Bessen & Marsh, 1994; Prusiner, 
1998; Telling et al., 1996).  Neuropathological profile can also be modified by route of infection, 
as inoculation-induced trauma from IC injection generated hippocampal plaques in a murine 
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scrapie model but are reduced or absent following IP inoculation (Bruce & Fraser, 1981). 
Modification of the prion protein itself can also alter neuropathological phenotype, as shown by 
cerebellar and brainstem deposits of amyloid-like plaques in mice not expressing the GPI anchor 
of PrP (Chesebro et al., 2005). 
  
Moreover, it is anticipated that these observations are providing clues about the timeline and 
mechanisms underlying prion pathogenesis. Focalized areas of neuropathology perhaps caught 
earlier in the progression of disease could provide insightful information about early 
neuropathological events preceding neuronal death but capable of causing terminal illness. Yun et 
al. observed the progression of lesion profiles in RML-infected C57BL/6J mice throughout 
multiple time points during disease. Specifically, his group witnessed lesions within the cervical 
spinal cord at 105dpi, in the brainstem at 123dpi, and then a more disseminated disease profile in 
142dpi terminally-ill mice. They also measured mRNA of heme oxygenase-1 (HO-1), as a maker 
of oxidative stress, and stained for GFAP and synaptophysin, a pre-synaptic vesicle membrane 
protein marker of synaptic loss (Honer, 2003). They found a progressive increase in HO-1 mRNA 
corresponding with later time points and advanced disease, an increase in GFAP over the course 
of time points sampled, and a significant decrease in synaptophysin expression. This study, and 
others, indicated an increased state of oxidative stress and evidence of synaptic loss as disease 
progressed (Johnston et al., 1997; Schipper, 2004; Yun et al., 2006). When considering the 
anatomy of the nervous system and the path of other neurotropic diseases (not disseminated to the 
brain through circulation), it makes sense that prions would result in a neuropathological lesion 
profile starting with peripheral nerves, ascend the spinal cord, affect brainstem and cerebellum 
then progress in a caudal to rostral fashion. This theory, however, would not take into account 
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prions that takes other routes for neuroinvasion, such as through circulation or olfactory 
epithelium.   
 
What is most interesting is how minimally-extensive apparent neuropathology was within clinical, 
terminally-ill mice infected with prions. Cases of prion-induced neuropathologies exist with both 
clinical symptoms in the absence of apparent disease—down to the histological level—as well as 
with evidence of significant PrPres deposition without fatal and/or transmissible disease (Piccardo 
et al., 2007). We believe that minimal neuropathology as evidenced by histological IHC/H&E 
staining and moderate but focal astrogliosis may have contributed to the overt lack of cytokine and 
chemokine expression within brain homogenates of infected mice. These findings, in addition to 
the considerations mentioned above, suggest that we do not have a good understanding of the 
cellular and signaling pathways that are resulting in apparent clinical disease. Clearly, it is 
warranted to further investigate synaptic loss and other potential mechanisms that might disrupt 
normal neuronal function prior to manifestation of histological and gross findings that are 
















PRO-INFLAMMATORY CYTOKINES AND MECHANISMS OF NEURONAL DEATH 
 
 
As extracellular signaling proteins involved in cell proliferation and differentiation, cytokines are 
useful for identifying the immune cellular players involved in prion pathogenesis. Certain 
cytokines have been proposed to play a direct role in neurodegeneration through activation of the 
transcription factor NADPH oxidase (NOX) (Griffin & Barger, 2010; Mrak & Griffin, 2005). 
Activation of NOX results in the production of reactive oxygen species (ROS) and may contribute 
to neuronal death and cognitive decline (Ansari & Scheff, 2011; Barth et al., 2009; Bruce-Keller 
et al., 2011). Interestingly, it has been shown that Aβ present in AD patients may activate the same 
NOX pathway as pro-inflammatory cytokines IL-1B, TNF-a, and IL-6 (Chiarini et al., 2005; Walsh 
et al., 2014). As mentioned previously, both PrPC-dependent signaling pathways and PrP106-126 
can upregulate pro-inflammatory cytokine gene expression and iNOS (Lu et al., 2012; Sonati et 
al., 2013). By blocking the interaction between Aβ and its co-receptor, PrPC, long-term 
potentiation and Aβ-induced cognitive deficits were prevented in an AD mouse model (Barry et 
al., 2011; Chung et al., 2010). 
 
Cofilin-actin rods are modified, space-occupying actin filaments within neuronal axons that 
interfere with vesicle transport and contribute to Aβ-induced synaptic loss (Bamburg et al., 2010; 
Cichon et al., 2012; Davis et al., 2009; Maloney et al., 2005; Minamide et al., 2000). A protein 
called RanBP9 is involved in cofilin activation, generation of ROS, and is also required in the Aβ-
induced apoptotic pathway (Roh et al., 2013). The biochemical environment necessary for rod 
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formation requires both dephosphorylation of cofilin and the presence of ROS to create disulfide-
linked cofilin dimers (Bernstein, 2012). Therefore, the neuroinflammation resulting from gliosis, 
which is present early on in TSEs and other neurodegenerative diseases, supports the formation of 
potentially neurotoxic rods. Conversely, rods may positively impact neuronal viability by blocking 
cofilin’s involvement in apoptotic pathways when it becomes completely oxidized (Bernstein et 
al., 2006).  
 
Longitudinal cytokine analysis of TgA20s over-expressing murine PrPC showed consistent 
expression of IL-2 and IL-5 in both scrapie-infected and NBH control mice. We attributed this to 
downstream effects associated with Prnp transgene insertion and/or over-expression of the prion 
protein itself. This transgenic model shortens incubation periods by expediting prion disease 
progression. One would hypothesize that prion-induced pathology would be increased in a disease 
model where the prion protein is over-expressed. However, we observed minimal vacuolation or 
spongiosis, and diagnosis of prion infection was made based off outward signs of terminal illness, 
PrPSc detection via Western blot, IHC staining in the caudal medulla and surrounding the third 
ventricle, and an increase in distribution and intensity of GFAP stain uptake in in RML-infected 
mice.  
 
These findings support the idea that cognitive decline and clinical disease during prion infection 
are a result of neuronal dysfunction (i.e. synaptic loss) prior to histologic evidence of neuronal 
loss. Both of these cytokines have indirect implications in immune-mediated peripheral prion 
replication (Alimzhanov et al., 1997; Koni et al., 1997; Matsumoto et al., 1997; Montrasio, 2000) 
as well as NGF synthesis/secretion (Awatsuji et al., 1993; Brodie & Gelfand, 1992; Ehrhard et al., 
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1993; Otten, Ehrhard, & Peck, 1989). Additionally, NGF appears to promote B cell growth and 
differentiation (Otten, Ehrhard, & Peck, 1989), is produced by specific T-helper subtypes (Ehrhard 
et al., 1993) and cooperatively stimulates expression of IL-2R on T lymphocytes (Brodie & 
Gelfand, 1992). This suggests some sort of feedback loop mechanism resulting in NF-κB 
activation and production of ROS through NOX expression and, ultimately, the production of 
cofilin-actin rods and synaptic loss.  
 
The presence of cytokines in neuronal cell culture was analyzed to confirm that Aβ was activating 
NOX-induced generation of ROS independent of cytokine signal transduction (Walsh et al., 2014). 
Aβ can stimulate the production of pro-inflammatory cytokines (Griffin & Barger, 2010), and it is 
known that cytokine profiles can vary widely between individuals affected by AD (Sudduth et al., 
2013). It appears that both Aβ and pro-inflammatory cytokines may be inducing the production of 
ROS in cells of the central nervous system, through a similar pathway but independent of each 
other.  Both Aβ and TNF-a can induce rod formation through a PrPC-dependent pathway, and 
importantly, overexpression of PrPC itself is sufficient to induce rod formation (Walsh et al., 2014). 
It may be that increased density of GPI-linked PrPC expression concentrated at lipid rafts within 
the cell membrane is influencing redox-signaling resulting in synaptic damage (Bate and Williams, 
2012; Brown & London, 1998), as lipid rafts are crucial players in synaptic development and 
maintenance (Mauch et al., 2001; Willmann et al., 2006). Mice lacking the GPI anchor of PrPC fail 





We now know that oxidative stress plays a role early on in many neurodegenerative disorders 
(Keller et al., 2005). In getting at the molecular signaling pathways that could be influencing 
protein-misfolding diseases, it is relevant to investigate endogenous as well as exogenous 
molecules/compounds. Dietary and environmental constituents such as ursolic acid (UA) and the 
micronutrients copper (Cu), manganese (Mn), magnesium (Mg), and iron (Fe) are the recent and 
current focus of many investigators studying neurodegeneration. UA is derived from the skin of 
many fruits and plants—blueberries, cranberries, basil, and rosemary, to name a few—and has 
many proposed health benefits (Ikeda et al., 2008; Kim et al., 2011; Kunkel et al., 2012; Prasad et 
al., 2012; Zhou et al., 2013). Briefly, UA has been shown to inhibit rod formation in neurons 
stimulated by both Aβ and pro-cytokines, specifically, TNF-α (Barth et al., 2012; Walsh et al., 
2014), and attenuate cognitive deficits (Mortiboys et al., 2013; Wang et al., 2011; Wu et al., 2013). 
 
 
The role of micronutrients is more complex. Copper binds to PrPC with high affinity on octapeptide 
repeats within the N-terminal region, inducing conformational changes (Brown et al., 1997a; 
Hornshaw et al., 1995;  Stӧckel et al., 1998; Whittal et al., 2000; You et al., 2012), and may 
possibly increase infectivity of PrPSc (Sigurdsson et al., 2003). The uptake of Cu into cells appears 
to involve cellular PrP (Brown, 1999; Pauly & Harris, 1998) as wild-type mice have higher 
membrane-bound Cu than Prnp-/- mice within the CNS where Cu is abundant (Brown et al., 1997a). 
The brains of CJD patients are reported to be deficient in Cu (Wong et al., 2003) as well as mice 
infected with scrapie, with the lowest levels corresponding with onset of clinical disease (Thackray 
et al., 2002; Wong et al., 2001). Mn has been shown to competitively bind with Cu on PrPC 
octapeptide domains (Brown et al., 2000). Copper may not be essential for PrP  PrPSc 
conversion, but its levels within the CNS throughout disease may play a role in signaling, synaptic 
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loss, and/or oxidative damage (Collinge et al., 1994; Vassallo & Herms, 2003). Decreased copper 
binding and/or knockout of PrPC has been correlated with diminished neuronal integrity and 
increased susceptibility to oxidative stress when infected with PrPSc (Brown et al., 1997b; Brown 
& Besinger, 1998; Miranda et al., 2000; Rachidi et al., 2003; Wong et al., 2000). Conversely, Cu+ 
and Fe2+ are known to generate ROS via Fenton-like or Haber-Weiss physiologic reactions 
(Butterfield & Stadtman, 1997; Halliwell & Gutteridge, 1990) and experimentally when stimulated 
by Aβ (Huang et al., 1999). It may be that distinct levels of micronutrients, as well as expression 
of amyloid/fibril-forming peptides and their precursors, may dictate the outcome of the particular 
disease state (Huang et al. 2004; Kralovicova et al., 2009; Multhaup et al., 1998; Opazo et al., 
2000; Opazo et al., 2003; Ruiz et al., 1999, Sigurdsson et al., 2003).  
 
In order to investigate the potential effects of metal cations on CWD prevalence and pathogenesis, 
water and soil were analyzed from CWD-endemic and non-endemic areas to quantitate individual 
concentrations of Cu, Mg, Mn, and Fe, as well as their associated ratios. Initial sampling by 
Nichols et al. (in process of submission) revealed high Mg ratios [Mg/Cu, Mg/Mn, and Mg/Fe] 
present in the water of CWD-negative areas, with Mg/Cu having the highest significance and thus 
receiving the most emphasis within the study. Transgenic Tg12 mice expressing elk PrPC were IC-
inoculated with CWD-positive or -negative brain homogenate and were offered a customized diet 
lacking Mg and Cu (Harlan/Teklad), with different treatment groups receiving various Mg/Cu 
ratios supplemented in drinking water offered ad lib. It was discovered that mice fed the custom 
diet which received the highest Mg/Cu drinking water, and also contained the lowest concentration 
of Cu, lived significantly longer than mice in other treatment groups. Although, interestingly, the 
levels of Cu within the brains of CWD-positive and –negative mice within the same group did not 
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differ significantly, while Mg concentration was significantly increased in CWD-positive animals 
from this same group.  
 
 
Differences in survival times between animals fed various ratios of Cu, Mg, Mn, and Fe, could be 
explained by metal cation effects on neuroinflammatory processes (Eikelenboom et al., 2002; 
Sigurdsson et al., 2003). In a murine scrapie model, experimental copper-chelation prolonged 
disease incubation period but simultaneously induced caspase-3—a pro-apoptotic factor—
overexpression in the cerebellum, midbrain, hippocampus and frontal cortex of infected mice 
(Bolea et al., 2010). In this same study yet another pro-apoptotic factor, Bax, was expressed in the 
medulla where it co-localized with PrPSc deposition, however caspase-3 nor Bax significantly 
contributed to neuronal loss. Although, caspase-3 has also been reported within the cerebellum of 
patients with CJD (Puig & Ferrer, 2001).  
 
 
To deduce whether or not pro-inflammatory mediators were present within the Tg12 cervidized 
elk mice, brain material was screened for a panel of chemokine and cytokine mRNAs using an 
RT-PCR, and protein quantitation was carried out using a Th1/Th2 cytokine multiplex assay. Some 
mice fed a high Cu diet showed alterations in mRNA transcripts for TNF-α and IFN-γ at terminal 
disease. To corroborate these results, it was determined that pro-inflammatory cytokines IL-1β, 
IFN-γ, and IL-18 were expressed in mice fed high [Cu], in addition to IL-2, IL-12p70, and IL-13. 
These results suggest that neuroinflammation may be occurring in CWD-infected mice exposed to 
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Bioplex Cytokine Array 
 
Table 1—Supplementary (sA & sB): TgA20 Cytokine Mega Table  
Mega table showing cytokine expression in TgA20 mice from the longitudinal cytokine study. 
Cytokine levels are shown in tables that are separated by treatment group, and by serum cytokine 
analysis (table 2A) or brain-homogenate cytokine analysis (table 2B). LPS-induced positive 
control mice are shown at the top of each table as a positive control. Expression of any analyte 
(within detectable limit of the standard curve) is shown by a colored cell background 
corresponding with the color of the analyte listed at the top of each table. Samples that were below 
detection limit (OOR<) are shown with a white background and defined as half of the lowest 
detectable limit (LDL) as determined by the lowest point on the standard curve for each analyte. 
(sA) Serum cytokine levels broken down by individual animals for each treatment group, then by 
dpi. (sB) Cytokine expression in brain homogenate of TgA20s, with RML groups pooled by gender 




























Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
133157-1 NBH M 0 0.28 0.15 0.14 0.14 0.15 0.3 5.52 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 22.91 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 11.41 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.045 0.115 12.44 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 12.14 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
133157-2 NBH M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 7.64 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 20.9 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 4.67 0.12 4.23 0.44 0.17 0.23 3.51 3.82 0.29
60 0.205 0.045 0.115 4.8 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 17.98 0.12 2.95 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.91 0.115 0.085 0.12 4.59 0.425 0.17 0.22 55.5 0.32 0.165
133157-3 NBH M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 16.05 0.44 ND
1 0.29 0.155 0.145 9.54 0.15 0.305 0.59 0.305 0.285 39.6 0.46 0.145
20 0.29 0.155 0.145 51.16 0.15 0.305 0.59 0.305 0.285 140.37 0.46 0.145
40 0.205 0.045 0.115 21.45 0.12 4.23 0.44 0.17 0.23 98.37 0.32 0.29
60 0.205 0.045 0.115 12.44 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 20.29 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
133157-4 NBH M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 12.61 0.15 22.79 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 41.41 0.15 4.24 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 21.93 0.12 9.26 0.44 0.17 0.23 66.94 0.32 0.29
60 0.205 0.045 0.115 1.19 0.12 3.83 0.44 0.17 0.23 3.51 0.32 0.29
133157-5 NBH M 0 0.28 0.15 0.14 0.14 0.15 0.3 7.65 0.3 0.29 23.63 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145






Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
133158-1 NBH F 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 14.35 0.15 4.09 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 2.61 0.12 5.11 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.045 0.115 0.09 0.12 7.53 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 8.21 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 2.85 0.425 0.17 0.22 3.58 0.32 0.165
133158-3 NBH F 0 0.28 0.15 0.14 0.14 0.15 3.62 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 7.94 0.15 12.8 0.59 0.305 0.285 39.6 0.46 0.145
20 0.29 0.155 0.145 8.68 0.15 3.94 0.59 0.305 0.285 39.6 0.46 0.145
40 0.205 0.045 0.115 3.16 0.12 6.76 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.045 0.115 2.8 0.12 3.64 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 7.52 0.12 3.57 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 3.47 0.425 0.17 0.22 3.58 0.32 0.165
133158-5 NBH F 0 0.28 0.15 0.14 0.14 0.15 3.54 0.58 0.3 0.29 25.36 0.44 ND
1 0.29 0.155 0.145 18.36 0.15 3.94 0.59 0.305 0.285 62.15 0.46 0.145
20 0.29 0.155 0.145 47.1 0.15 5.42 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 22.17 0.12 3.83 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.045 0.115 23.62 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
80 0.205 0.04 0.115 23.5 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
136540-1 NBH F 0 0.18 0.045 0.11 10.6 0.12 2.78 0.445 0.175 0.215 117.39 0.315 0.155
1 0.18 0.045 0.11 0.08 0.12 27.97 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 0.08 0.12 3.34 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 0.08 0.12 5.24 46.32 0.175 0.215 94.54 0.315 0.155
136540-2 NBH F 0 0.18 0.045 0.11 16.55 0.12 7.19 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 1.83 0.11 23.88 0.12 11.06 0.445 0.175 0.215 2.885 3.8 0.155
20 0.18 0.045 0.11 36.97 0.12 29.18 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 26.18 0.12 27.2 0.445 0.175 0.215 2.885 0.315 0.155






Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
133707-1 RML M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 27.21 0.15 0.305 0.59 0.305 0.285 122.17 0.46 0.145
20 0.29 0.155 0.145 34.32 0.15 0.305 0.59 0.305 0.285 81.66 0.46 0.145
40 0.205 0.045 0.115 21.78 0.12 0.22 0.44 0.17 0.23 72.04 0.32 0.29
60 0.205 0.045 0.115 27.02 0.12 5.79 0.44 0.17 0.23 56.35 0.32 0.29
80 0.205 0.04 0.115 30.42 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
133707-2 RML M 0 0.28 0.15 0.14 4.48 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 31.12 0.15 8.6 0.59 0.305 0.285 74.12 0.46 0.145
20 0.29 0.155 0.145 38.81 0.15 0.305 0.59 0.305 0.285 66.24 0.46 0.145
40 0.205 0.045 0.115 13.94 0.12 2.64 0.44 0.17 0.23 72.04 0.32 0.29
60 0.205 0.045 0.115 12.84 0.12 4.91 0.44 0.17 0.23 74.54 0.32 0.29
80 0.205 0.04 0.115 5.88 0.12 2.74 0.425 0.17 0.22 84.43 0.32 0.165
133707-4 RML M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 3.94 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 40.47 0.15 5.13 0.59 0.305 0.285 157.65 0.46 0.145
40 0.205 0.045 0.115 18.54 0.12 4.03 0.44 0.17 0.23 81.91 0.32 0.29
60 0.205 0.04 0.115 4.98 0.12 2.53 0.425 0.17 0.22 100.63 0.32 0.165
134097-1 RML M 0 0.28 0.15 0.14 1.56 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 28.62 0.15 0.305 0.59 0.305 0.285 197.8 0.46 0.145
20 0.29 0.155 0.145 56.51 0.15 0.305 0.59 0.305 0.285 95.94 0.46 0.145
40 0.205 0.045 0.115 37.92 0.12 0.22 15.07 0.17 0.23 122.65 0.32 0.29
60 0.205 0.04 0.115 25.42 0.12 0.21 0.425 0.17 0.22 82.05 0.32 0.165
134097-2 RML M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 8.68 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 2.22 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 3.52 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 3.19 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 0.04 0.115 5.05 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165







Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
134097-3 RML M 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 0.09 0.12 2.64 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.79 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 0.04 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
134097-4 RML M 0 0.28 0.15 0.14 0.72 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 6.31 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 21.63 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 19.29 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 16.55 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 0.04 0.115 13.93 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
136539-1 RML M 0 0.18 0.045 0.11 0.08 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 0.08 0.12 4.44 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 11.69 0.12 2.49 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 3.29 0.12 3.62 0.445 0.175 0.215 2.885 0.315 0.155
60 0.2 0.05 0.115 7.24 0.12 5.77 0.44 0.17 0.22 56.75 0.32 0.145
80 0.2 0.05 0.115 8.89 0.12 4.76 0.44 0.17 0.22 30.19 0.32 0.145
Term 4.08 0.05 2.04 3.61 0.12 4.76 0.44 0.17 0.22 102.32 0.32 0.145
136539-2 RML M 0 0.18 0.045 0.11 1.9 0.12 3.06 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 7.83 0.12 3.06 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 8.67 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 3.52 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
136539-3 RML M 0 0.18 0.045 0.11 41.03 0.12 6.55 0.445 0.175 0.215 79.39 0.315 0.155
1 0.18 0.045 0.11 17.59 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 36.28 0.12 3.89 0.445 0.175 0.215 49.63 0.315 0.155







Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
134908-1 RML F 0 0.28 0.15 0.14 0.92 0.15 0.3 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 28.46 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.29 0.155 0.145 63.95 0.15 7.74 0.59 0.305 0.285 3.3 0.46 0.145
40 0.205 0.045 0.115 37.15 0.12 10.97 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 24.24 0.12 4.18 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 0.04 0.115 25.99 0.12 3.37 0.425 0.17 0.22 3.58 0.32 0.165
134098-2 RML F 0 0.28 0.88 0.14 0.14 0.15 1.52 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.205 0.045 0.115 4.25 0.12 20.73 0.44 0.17 0.23 42.15 0.32 25.06
40 0.205 10.05 0.115 4.46 0.12 22.77 10.77 0.17 0.23 3.51 0.32 28.07
60 0.205 8.54 0.115 6.92 0.12 16.65 0.425 0.17 0.22 42.96 0.32 0.165
80 0.205 7.32 0.115 6.35 0.12 10.17 0.425 0.17 0.22 3.58 0.32 3.53
Term 0.18 10.41 0.11 17.46 0.12 13.23 0.445 0.175 0.215 2.885 0.315 0.155
134098-3 RML F 0 0.28 0.15 0.14 0.14 0.15 1.44 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 0.13 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.205 0.045 0.115 0.09 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
40 0.205 0.045 0.115 0.09 0.12 2.64 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 0.085 0.12 7.14 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 1.13 0.115 0.085 0.12 7.14 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.205 0.04 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
134098-4 RML F 0 0.28 0.15 0.14 0.14 0.15 1.4 0.58 0.3 0.29 4.015 2.09 ND
1 0.29 0.155 0.145 31.07 0.15 12.8 0.59 0.305 0.285 3.3 0.46 0.145
20 0.205 0.045 0.115 16.96 0.12 5.21 0.44 0.17 0.23 3.51 0.32 0.29
40 0.205 0.045 0.115 25.2 0.12 6.28 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 20.77 0.12 6.94 0.425 0.17 0.22 3.58 0.32 0.165
80 0.205 0.04 0.115 28.79 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165




















Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 0.115 0.09 0.12 10.15 8.46 0.17 0.22 3.315 7.09 0.145
140726 LPS F n/a 0.2 0.88 2.36 0.09 0.12 29.69 160.17 5.93 0.22 64.51 29.41 19.04
134098-5 RML F 0 0.28 0.15 0.14 0.14 0.15 0.3 0.58 0.3 0.29 21.84 0.44 ND
1 0.29 0.155 0.145 16.45 0.15 6.01 0.59 0.305 0.285 95.94 0.46 0.145
20 0.205 0.045 0.115 24.16 0.12 7.44 0.44 0.17 0.23 116.19 0.32 7.84
40 0.205 0.045 0.115 13.91 0.12 6.37 0.44 0.17 0.23 75.79 0.32 0.29
60 0.205 0.04 0.115 9.23 0.12 3.37 0.425 0.17 0.22 48.65 0.32 0.165
80 0.205 0.04 0.115 23.3 0.12 6.56 0.425 0.17 0.22 3.58 0.32 0.165
Term 0.18 0.045 0.11 0.08 0.12 7.19 17.82 0.175 0.215 2.885 0.315 0.155
135588-2 RML F 0 0.28 0.15 0.14 1.24 0.15 1.68 0.58 0.3 0.29 4.015 0.44 ND
1 0.29 0.155 0.145 12.15 0.15 0.305 0.59 0.305 0.285 3.3 0.46 0.145
20 0.205 0.045 0.115 20.65 0.12 5.69 0.44 0.17 0.23 3.51 0.32 0.29
40 0.205 0.045 0.115 18.35 0.12 5.21 0.44 0.17 0.23 3.51 0.32 0.29
60 0.205 0.04 0.115 17.58 0.12 2.95 0.425 0.17 0.22 3.58 0.32 0.165
135588-4 RML F 0 0.28 0.15 0.14 0.8 0.15 2.39 0.58 0.3 0.29 18.06 2.09 ND
20 0.205 0.045 0.115 2.61 0.12 0.22 0.44 0.17 0.23 3.51 0.32 0.29
40 0.205 0.045 0.115 1.08 0.12 11.07 0.44 0.17 0.23 53.61 0.32 0.29
60 0.205 0.04 0.115 0.085 0.12 5.38 0.425 0.17 0.22 42.96 0.32 0.165
80 0.205 0.79 0.115 0.085 0.12 0.21 0.425 0.17 0.22 3.58 0.32 0.165
136550-1 RML F 0 0.18 0.045 0.11 18.68 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 13.14 0.12 7.32 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 22.88 0.12 16.54 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 9.23 0.12 4.97 0.445 0.175 0.215 60.89 0.315 0.155
60 0.2 0.05 0.115 10.3 0.12 5.77 0.44 0.17 0.22 56.75 0.32 0.145
136550-2 RML F 0 0.18 0.045 0.11 9.31 0.12 7.19 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 11.02 0.12 4.17 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 10.02 0.12 4.97 0.445 0.175 0.215 2.885 0.315 0.155
40 0.18 0.045 0.11 14.74 0.12 2.49 0.445 0.175 0.215 2.885 0.315 0.155
60 0.2 0.05 0.115 5.19 0.12 2.67 0.44 0.17 0.22 3.315 0.32 0.145
80 0.2 0.05 0.115 10.22 0.12 4.5 0.44 0.17 0.22 3.315 0.32 0.145
136550-3 RML F 0 0.18 0.045 0.11 7.57 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 6.38 0.12 3.06 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 12.53 0.12 4.71 0.445 0.175 0.215 2.885 0.315 0.155
40 0.2 0.05 0.115 6.81 0.12 7.25 0.44 0.17 0.22 44.26 0.32 0.145
136550-4 RML F 0 0.18 0.045 0.11 15.02 0.12 3.62 0.445 0.175 0.215 2.885 0.315 0.155
1 0.18 0.045 0.11 7.14 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155
20 0.18 0.045 0.11 12.46 0.12 0.21 0.445 0.175 0.215 2.885 0.315 0.155





















Animal ID TX Grp M/F DPI GM-CSF IFN-ϒ IL-1β IL-2 IL-4 IL-5 IL-6 IL-12p70 IL-13 IL-18 TNF-α IL-10
141158 LPS M n/a 0.2 0.05 4.28 3.36 0.12 0.22 0.44 0.17 0.22 421.18 0.32 47.62
140726 LPS F n/a 0.2 0.05 4.79 2.71 0.12 0.22 0.44 0.17 0.22 335.1 0.32 33.17
133157-5 NBH M 40 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 504.64 0.32 44.87
133157-4 NBH M 60 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133157-3 NBH M 80 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133157-1 NBH M 158 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133157-2 NBH M 158 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
136540-1 NBH F 40 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
136540-2 NBH F 60 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133158-5 NBH F 80 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133158-1 NBH F 158 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133158-3 NBH F 158 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
136539-2/136539-3 RML M 40 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133707-4/134097-1 RML M 60 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
133707-1/133707-2 RML M 80 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
134097-2 RML M 120 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
136539-1 RML M 121 0.2 1.71 0.115 6.36 0.12 0.22 0.44 0.17 4.81 478.03 0.32 44.87
134097-4 RML M 128 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
134907-3 RML M 144 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
136550-3/136550-4 RML F 40 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
135588-2/136550-1 RML F 60 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
135588-4/136550-2 RML F 80 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
134908-3 RML F 100 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145
134098-5 RML F 100 0.2 0.05 0.115 0.09 0.12 0.22 0.44 0.17 0.22 3.315 0.32 0.145





A.  B.  
 
C.   D.  
 
(Figure 16—Supplementary): GFAP—Low Magnification Images 
Same images and mice as Figure 16 viewed here at low-power magnification to illustrate GFAP 
staining in the medulla at the level of the cerebellar peduncles. Intensity of GFAP staining is less 
in NBH-inoculated mice (A & B) compared with what was observed in RML-inoculated mice (C 
& D).   
 
 
 
 
 
 
